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Abstract
Successful administration of chemotherapeutic agents for cancer treatment requires a
balance between the efficacy and the safety of the drug. This often limits physicians to a very
narrow therapeutic window. To avoid the harmful side-effects, chemotherapeutic agents may be
administered at a suboptimal dose. This is not only a less effective treatment, but can lead to the
development of drug resistance by cancerous cells. The therapeutic window can be increased
through targeted, stimuli-responsive delivery, which increases the drug concentration at the
diseased site, and releases or activates the drug only when it reaches the target. Cancer is a
highly variable disease occurring in many organs. There is a need for delivery systems that are
easily adaptable for a number of targets in different forms of cancers, and that can accommodate
various cytotoxic drugs. The motivation of this project was to develop flexible synthesis
procedures for the targeted delivery of chemotherapeutic agents. In this work, we have
synthesized and tested three drug delivery systems.
The first system is a dextran-based polymer conjugate designed to preferentially deliver
doxorubicin to hepatocytes. Doxorubicin has been conjugated to dextran of different molecular
weights, with varying degrees of galactose substitution. The degree of doxorubicin substitution
was maintained by performing the conjugation of doxorubicin and galactose in two sequential
steps. The synthesis scheme was simple, efficient and easily adaptable to other therapeutic
agents and targeting moieties with free amine groups. In cell culture studies on target
hepatocytes, the dextran-doxorubicin-galactose (DDG) conjugates showed lower toxicity
compared to doxorubicin, increased toxicity with higher molecular weight polymers, and greater
toxicity with higher degree of galactose substitution. Experiments in the control cell lines
showed increased toxicity for higher molecular weight polymers; however, there was no effect
due to the presence of galactose. At diameters of 15-40 nm, the polymer conjugates were too
large to enter the cell nuclei in large quantities; however, a sufficient amount of doxorubicin
entered the nuclei to cause cell death. The higher molecular weight polymers were more
effective as they had a higher chain loading of doxorubicin.
In spite of significant uptake of the targeted conjugates, the cytotoxicity of the first
system was limited since the doxorubicin remained attached to the polymer. For the second
system, pH-sensitive dextran-doxorubicin conjugates of different molecular weights were
synthesized. The doxorubicin was attached to the dextran backbone through a hydrazone bond.
These polymer conjugates were stable at a physiological pH of 7.4, but released over 70% of the
attached doxorubicin within 24 h at a pH of 5.0. The rate of release was found to be faster for
the lower molecular weight polymers. In cell culture studies, the conjugates showed significant
cytotoxicity. The effect of lower chain loading of doxorubicin for the lower molecular weight
polymers was offset by the rapid initial release; these polymers showed slightly greater toxicity.
Live confocal microscopy indicated that the conjugates were internalized by cells within minutes
after incubation. Since release of doxorubicin from the conjugates was much slower than
cellular trafficking, it is possible that the conjugates went through multiple endocytosis and
exocytosis cycles before the doxorubicin was released. Doxorubicin from the dextran-
hydrazone-doxorubicin (DHD) conjugates was found to localize almost exclusively in the nuclei
of cells. Since doxorubicin attached to dextran with a stable bond showed limited localization in
the nuclei, this indicated that doxorubicin from the acid-labile conjugates was released after
internalization by cells. The cytotoxicity of the DHD conjugates was significantly greater than
the stable DDG conjugates due to the release of doxorubicin inside cells.
In the third system, the targeting and pH-sensitivity functionalities were combined by
expressing galactose on an amphiphilic, temperature- and pH-sensitive copolymer of N-
isopropylacrylamide (NIPAAm), N,N-dimethylacrylamide (DMAAm) and 10-undecenoic acid
(UA). The polymer self-assembled in aqueous medium, and was used to encapsulate paclitaxel.
Various synthesis parameters were adjusted to yield polymers that achieved high drug loading
and rapid release in a temperature- and pH-responsive manner. The appropriate lower critical
solution temperature (LCST) was obtained by adjusting the content of DMAAm and UA to
change the hydrophilicity of the polymer. The hydrophilicity of UA was dependent on pH and
thus, made the polymer pH-sensitive. Galactose was attached to the end-group of the copolymer
to target it to hepatocytes. The drug loading, particle size and release rate were affected by the
polymer molecular weight. Paclitaxel was encapsulated in particles that released nearly 100% of
the drug within 24 h at a pH of 5.0 at 370 C. In the target hepatocyte cell line, the stimuli-
responsive, galactose-expressing particles were significantly more toxic than the non-stimuli-
responsive as well as the non-targeted particles. In the control cell line, the presence of galactose
did not have any effect on cytotoxicity.
In summary, we have synthesized three targeted drug delivery systems. The DDG
conjugates successfully targeted hepatocytes by expressing galactose. The DHD conjugates
would be retained in tumors due to the enhanced permeability and retention effect, and release
the drug at the target site. The galactose-targeted paclitaxel-loaded particles synthesized from
the temperature- and pH-sensitive polymer achieved a remarkable increase in toxicity in the
target cell line, while maintaining base toxicity in the control cell line. Both the amount of drug
delivered and the rate of release were found to be important in the efficacy of the drug delivery
vehicles.
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Chapter 1 - Background and Motivation
1.1 Limitations on Conventional Cancer Treatment
Cancer is the growth of a population of cells with a genetic abnormality, which results in
unrestrained cell division. In the early stages, the cancerous cells accumulate to form a localized
tumor. If the tumor is malignant and remains undetected, it can metastasize and form secondary
tumors in other organs. Cancer is the second leading cause of death after heart disease in the
USA. Over 10.5 million people in the USA have or have had some form of cancer, and over two
million new cases are expected in 2007 [1]. The five-year relative survival rate for all types of
cancer is only 66% [1]. Conventional treatment involves various combinations of surgery,
radiation therapy and chemotherapy. Radiation and chemotherapy are used if the cancer is
inoperable or metastasized, and also as follow-up to surgery. In addition, immunotherapy and
hormone therapy have been used in the treatment of certain forms of melanoma, breast and
prostate cancers [2].
Chemotherapeutic agents are cytotoxic drugs, which affect any cells in the body that are
actively dividing. The side-effects can include nausea, vomiting, immunosuppression, mucositis,
hepatotoxicity, nephrotoxicity, memory loss, anemia and even death. Several chemotherapeutic
agents also have long-term side-effects in major organs such as the heart, lungs, kidneys and
central nervous system [1]. To avoid these adverse effects, conventional chemotherapeutic
agents must be administered at a safe, but suboptimal dose, which is insufficient to treat the
cancer satisfactorily in one session [3]. Physicians have attempted to treat cancer using these
lower doses over a longer period of time, however, this is often ineffective due to the
development of drug resistance by the cancerous cells [3]. Currently, patients are given
"combination chemotherapy" - multiple drugs at various doses to try to circumvent these
problems.
Newer treatments such as tumor vaccines and small-molecule therapies avoid many of
the side-effects by targeting surface or intracellular proteins specific to the cancer being treated.
However, these methods can only deal with very specific diseases. Cytotoxic drugs can be used
to treat several types of cancers, and would be highly effective if they entered only cancerous
cells. The limitations in conventional cancer treatment can be alleviated by targeted drug
delivery, which is a vehicle that will preferentially carry the drug to the target site in the body,
and thereby reduce the amount of drug in the rest of the body that can cause undesired side-
effects. This would increase the range in which a drug is both safe and effective.
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Fig. 1.1. Schematic illustration of differences between cancerous and healthy tissues [4].
There are a number of strategies that have been investigated to target tumors. Fig. 1.1
shows the basic physiological differences between healthy and cancerous tissues. As shown,
tumors have leaky blood vessels and tight lymphatic capillaries, which allow them to take up and
retain large molecules or particles. This is called the enhanced permeability and retention (EPR)
effect, and has been used to passively target macromolecules or particles to tumors since uptake
by normal tissue is comparatively lower. Yuan et al. conducted a study to determine size gaps
between cells in tumor blood vessels. They found that while tumor vasculature permeability was
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both temporally and spatially heterogeneous, the pore size ranged from 200-600 nm with a mean
of 400 nm [5, 6]. Another difference between tumors and healthy tissue is that the pH in a tumor
is on average 7.0 and widely variable, as compared to a pH of 7.4 in normal tissue [7]. Thirdly,
cancerous cells may differ from normal cells in their protein expression and morphology, and in
the ability to form new blood vessels or angiogenesis. Many researchers are utilizing one or
more of these differences to achieve targeted treatment of cancer. A targeted drug delivery
system can have several features, which are addressed in the next section.
1.2 Targeted Drug Delivery Systems
1.2.1 Drug Carrier
After administration, a targeted drug delivery vehicle must remain in circulation long
enough to locate the target cells or organ, bind to them, and stimulate the appropriate response.
This has been a challenge because drugs are usually low molecular weight molecules that are
rapidly cleared from the plasma [8-10]. Residence time of drugs in the body can be increased by
various means, including conjugation to polymers, and encapsulation in particles, micelles or
liposomes.
Polymeric conjugates can enhance the performance of a drug in several ways. They
increase the circulation time in the plasma, protect the drug from various enzymes and the
immune system, and decrease non-specific toxicity [11, 12]. Chemical modification of polymers
also allows addition of functionalities, such as receptor targeting and stimuli-responsive
activation of the drug. Another advantage is that polymer-bound drugs are less likely to be
expelled from multidrug-resistant cells [13]. Conversely, conjugation to a polymer results in
reduced therapeutic effect compared to the free drug. Polymers that have been used for drug
delivery include poly(lactic acid) (PLA), poly(glycolic acid), poly(ethylene glycol) (PEG),
poly(L-lysine), poly(ethylene oxide), poly(c-caprolactone) (PCL), N-isopropylacrylamide
(NIPAAm), poly(methyl methacrylate), poly((N-2-hydroxypropyl)methacrylamide) (HPMA),
chitosan and dextran, as well as various copolymers of these and other polymers [13-21 ].
Many researchers have studied the interaction of particles with cells both in vitro and in
vivo. A critical parameter is the size of the particles. Micrometer-sized particles can induce an
immune response in vivo and are not taken up by many cell types [9]. Nanoparticles smaller than
100-150 nm have been found to be efficiently taken up in cell culture, perfusion and in vivo
studies [22-24]. Our preliminary experiments using inert nanoparticles have shown that particles
up to 200 nm diameter were taken up by hepatocytes in cell culture. Mitra et al. have
synthesized chitosan nanoparticles of 100 nm diameter, and found that they were retained in
tumors due to the EPR effect in a mouse cancer model [21].
PEG has been used by many researchers as the hydrophilic end of amphiphilic
copolymers to form micelles for drug delivery. Micelles formed from PLA-PEG block
copolymers were found to accumulate in the liver in in vivo studies [25]. When this copolymer
was used to encapsulate doxorubicin, the micelles were stable and degraded over a period of five
weeks [26]. These systems degrade very slowly and have no tunable release mechanism.
Micelles formed from copolymers of PEG and PCL have been studied for the delivery of
rapamycin. Rapamycin from these micelles was also released in a non-specific manner;
however, they achieved full release in 6 days [27].
Liposomes can be used to deliver hydrophilic therapeutics. Some of the biggest
challenges in liposomal delivery are that they are often leaky, have non-specific release, and fuse
very easily with the cell membrane. Simoes et al. have worked on making liposomes stimuli-
responsive using the pH-sensitive lipid phosphatidylethanolamine, and longer circulating by
attaching PEG to the lipid to stabilize it in plasma. The liposome is also targeted to the H-2k
antigen, which is expressed on several types of tumors [28]. Zignani et al. imparted pH
sensitivity to their egg phosphatidylcholine-cholesterol liposomes by incorporating NIPAAm
copolymers into the lipid bilayer. They achieved 45% release after 16 h, and found that release
was proportional to NIPAAm content [29].
1.2.2 Mechanism for Targeting
The key to successful targeting is to find a detectable difference between the target and
the rest of the body. A promising method is protein-targeted delivery. In recent years, much
attention has been given to ligand-binding receptor proteins, such as hormone and growth factor
receptors, antigens (antibody receptors) and lectins (carbohydrate receptors) expressed on the
cell surface in a tissue-specific manner. For example, macrophages and hepatocytes express
high concentrations of mannose and galactose binding sites, respectively [4, 30]. As mentioned
before, cancer can cause a change in the expression of cell surface receptors. In particular,
growth factor receptors, certain antigens and lectins are expressed on cancerous tissue at a higher
concentration than on their healthy counterparts [13, 19, 31]. Transferrin and growth factors aid
in cell division and their receptors are expressed in high concentrations in several types of
cancers [32, 33]. The folate receptor is expressed in a high concentration in various forms of
cancer, such as ovarian, lung, breast and colon cancer [34-36].
Targeting cancerous cells is challenging because the target cells can be spread throughout
the whole body at a low concentration compared to the healthy cells. Also, the receptors being
targeted are present on healthy cells as well, though at lower concentrations [37]. The success of
this method is dependent on the higher local concentration of receptors on cancerous cells,
resulting in more frequent binding of the drug delivery vehicle.
The antibody-antigen recognition system has been studied extensively recently, and a few
drugs utilizing its potential are on the market or in clinical trials [10, 37, 38]. Some of the
obstacles in antibody-targeted delivery include low tumor penetration, immunogenicity, poor
internalization, and low and variable antigen density [31, 32]. Antibody-antigen binding has
high affinity, which causes the drug delivery vehicle to bind strongly to the target. However, due
to the strong binding, the vehicle may not be able to penetrate the tumor or tissue very effectively
[37]. If an intact antibody is used for targeting, there would be a higher chance for the vehicle to
be detected by the immune system and cleared rapidly [37, 39]. Antigens often recognize
multiple antibodies that have a similar binding site, which lowers the specificity [39]. Since
antibodies and antigens are proteins, their binding sites are dependent on the integrity of the
three-dimensional amino acid structures. Processing of antibodies during synthesis of a delivery
system may negatively affect this binding site, and lower the specificity and/or the binding
affinity.
Despite all of these limitations, much research is being conducted in the area of antigen-
targeted delivery, and a number of potential targets have been identified. Dillman et al. have
worked on targets from several different types of cancers, including chronic lymphocytic
leukemia and cutaneous T-cell lymphoma, and non-small cell lung carcinoma [40, 41]. They
synthesized conjugates of anti-human T-cell antibody and doxorubicin. They have also
conjugated daunorubicin to the antibody with an acid-labile bond, and found improved
performance in cell culture studies and a mouse model [42]. The HER2 receptor in breast cancer
and tranferrin, and HER2/neu in immortalized breast cancer cell lines have been investigated.
Doxorubicin-loaded liposomes expressing anti-HER2 were used to successfully treat tumors in
animal models for breast cancer [43]. In breast cancer cell lines, certain combinations of
immunotoxins targeting different antigens were found to have a synergistic cytotoxic effect [44].
Human chorionic gonadotropin receptors on breast cancer cell lines were also used as a target,
and a ten-fold increase in cytotoxicity was observed using the targeted vehicle [45].
The lectin-carbohydrate system is a comparatively new area of study and shows great
potential [9, 13, 19, 39, 46, 47]. It offers a few advantages over antibody-directed delivery. The
dissociation constant for lectin-carbohydrate binding is in the millimolar to micromolar range,
compared to the micromolar to picomolar range for antigen-antibody binding. The lower affinity
between lectins and carbohydrates allows for greater tumor penetration [37, 48-51]. Also, the
affinity can be increased with a higher density of carbohydrates expressed on the delivery vehicle
[52]. A significant advantage of lectin targeting is that when carbohydrates on glycoproteins
bind to their specific lectins, the resulting complex is taken into the cell by the process of
receptor-mediated endocytosis (RME). RME is a rapid mechanism to internalize certain
receptor-ligand complexes [53, 54]. Antigens usually do not undergo RME, however, they can
get internalized by non-specific endocytosis, which is slower than RME [55]. Additionally,
simple carbohydrates or carbohydrate chains are more robust and easier to work with than
proteins. They are unlikely to become modified due to temperature, solvents or chemical
processing.
Some potential lectin targets have been identified recently, such as the receptors for
wheat germ agglutinin and peanut agglutinin on colon tissue for cancer or other diseases of the
colon [17]. Colon adenocarcinomas have also been shown to express receptors for a-galactose,
a-glucose and N-acetyl-j3-glucosamine [52, 56]. Monsigny et al. have shown that murine
leukemia cells express a high concentration of L-fucose receptors, and are studying the use of
glycoconjugates for gene delivery [19]. Yamazaki et al. have attached glycoproteins to the
surface of liposomes for targeted drug delivery [57].
1.2.3 Drug Release
A high percentage of macromolecules, proteins or particles taken up by endocytic
pathways is trafficked to lysosomes and subsequently degraded [58]. However,
chemotherapeutic agents must usually enter the nucleus of cells to cause cell cycle arrest or cell
death. Whether the drug is conjugated to polymers or encapsulated within particles, micelles or
liposomes, it must be released once it has reached the target site. If it is delivered in a conjugate
form or in a slightly altered form due to synthesis, it must remain potent.
Fig. 1.2 is a schematic representation of RME of a hypothetical protein. After the ligand
on the protein binds to its receptor on the cell surface, the complex is trapped in a clathrin-coated
pit (1). Once enough receptor-ligand complexes occupy a coated pit, the clathrin polymerizes
further and forms a separate vesicle in the cell cytosol (2). The clathrin then depolymerizes,
allowing the vesicle to fuse with an endosome (3). The influx of H+ and CF ions cause a
lowering of the pH of the endosome from 7.4 to - 5.0, causing the receptor and ligand to
dissociate (4). The receptors are then usually recycled back to the cell surface as rapidly as every
10-20 min (5) [55]. The ligands may diffuse into the cytosol, or be transported to a lysosome,
depending on its function in the cell.
Lysosomes contain many proteases and enzymes that may degrade the drug, therefore the
drug must be released from the delivery vehicle in the endosome. Strategies for endosomal
escape include endosomal disruption, enzyme-degradable crosslinkers and pH-sensitive release.
Subbarao et al. performed studies on pH-dependent peptide disruption of lipid bilayers [59],
which was put into use for endosomal disruption by researchers working on drug delivery.
Murthy et al. have worked on a polymer with a PEG-shielded membrane-disruptive backbone.
The PEG was released from the backbone in the low pH of the endosome, and the exposed acetal
backbone broke open the endosome. Their experiments showed successful disruption of red
blood cell membranes [58]. Duncan et al. have synthesized HPMA-drug conjugates with a
peptide linker (Gly-Phe-Leu-Gly), which could be degraded by lysosomal proteases such as
cathepsin B [60]. HPMA has also been conjugated to drugs using pH-sensitive hydrazone or cis-
aconytil bonds. Its cytotoxicity in cell culture studies was found to be greater than for conjugates
with an enzymatically degradable peptide [61]. Yoo et al. studied pH-sensitive release using two
synthesis strategies with a block copolymer of PLA and methoxy-poly(ethylene glycol). They
found that the hydrazone bond performed much better than the acetal bond in terms of drug
release and in vitro cytotoxicity. However, their polymer self-assembled to form micelles and
released only - 40% of the drug over 24 h, and took up to 25 days to release the full amount
[62].
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Fig. 1.2. Schematic of RME (adapted from [55]).
1.3 Project Goals
Cancer is a highly variable disease occurring in many organs. The variation is significant
enough that cancer of each organ is treated as a separate disease. In spite of significant progress
in the last few decades in the field of targeted drug delivery, more work is needed in improving
target recognition, minimizing premature release, optimizing release at the target, and preserving
drug efficacy despite chemical alteration [8, 12, 63]. There is a need for delivery systems that
are easily adaptable for a number of targets in different forms of cancers, and that can
accommodate various cytotoxic drugs.
In this work, we have synthesized and tested three drug delivery systems for the delivery
of chemotherapeutic agents. The first system is a dextran-based polymer conjugate designed to
preferentially deliver doxorubicin to hepatocytes (Chapter 2). The second system is a pH-
sensitive conjugate of dextran and doxorubicin, which releases the drug at low pH (Chapter 3).
The third system is a temperature- and pH-sensitive copolymer that expresses a targeting moiety,
and is used to encapsulate a hydrophobic drug and deliver it to hepatocytes in a pH-sensitive
manner (Chapter 4).
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Chapter 2 - Synthesis, Characterization and In Vitro Studies of Dextran-Galactose
Conjugates for Targeted Doxorubicin Delivery to Hepatocytes
2.1 Introduction
Hepatocyte cell lines have been extensively studied and are well-known to express a high
concentration of the asialoglycoprotein (ASGP) receptor. This receptor has a selective and high
affinity for proteins or carbohydrate structures terminating with galactose [1]. Researchers have
shown that ligand binding leads to receptor-mediated endocytosis of the complex [1-4]. In
addition to being a well-characterized model system, hepatocytes are a good target for the
treatment of various diseases such as lysosomal storage disease, hepatitis and parasitic diseases
(e.g. malaria) [1]. Trere et al. have shown that while normal liver cells express the ASGP
receptor in a polarized manner on the luminal and lateral faces, on human hepatocellular
carcinomas there is increased expression of the receptor on all surfaces of the cells [2].
Additionally, it has been found that in freshly isolated hepatocytes, internalization of the
receptor-ligand complex does not reduce the number of receptors available on the cell surface
due to recycling. The ligand-receptor complex dissociates at a low pH, and the receptor is
transported back to the cell surface before the endosome fuses with a lysosome [3]. Studies by
Anderson et al. have confirmed that the uptake of polymer-galactose conjugates were
temperature- and adenosine triphosphate (ATP)-dependent, and could be competitively inhibited,
indicating that synthetic macromolecules expressing galactose also undergo receptor-mediated
endocytosis [4].
Many researchers have studied the uptake of drugs, proteins, polymers and particles
modified to express galactose, and found enhanced association with hepatocytes [5-8].
Galactose has been conjugated to a number of polymers including dextran, poly(ethylene glycol),
poly((N-2-hydroxypropyl)methacrylamide) (HPMA) and poly(L-lysine) [5-10]. Both in vivo and
in vitro testing have shown specific uptake of galactosylated moieties by the liver or by
hepatocyte cell lines expressing the ASGP receptor. This enhanced interaction was found to be
dependent on the concentration of galactose on the material being tested. Cairo et al. have
performed binding studies on a multivalent receptor on polymer scaffolds, and shown that
increasing the density of binding sites on a ligand increased the stoichiometry of interaction
(number of binding moieties per receptor), the rate of interaction and the receptor proximity [ 11].
Ogawara et al. studied uptake of bovine serum albumin (BSA) conjugated to galactose at varied
stoichiometries in perfused rat liver. The hepatic clearance was found to increase significantly as
the number of galactose residues per BSA molecule was increased [12] Several researchers have
worked on conjugates of HPMA with galactose and doxorubicin and tested them in vitro and in
vivo. The galactose-targeted material showed improved uptake compared with the non-targeted
polymer [10, 13-15]. David et al. have studied the effect of galactose, lactose and a branched
multiple-galactose molecule in hepatocellular carcinomas using HPMA [15]. Ohya et al. have
worked on cisplatin delivery using branched galactose residues. Even though the cisplatin was
modified in the synthesis, it was still found to be effective in cell culture [16]. Hashida et al.
have studied the effect of molecular weight, galactose configuration, and dose on the delivery of
galactose-attached polymers and proteins [17].
Doxorubicin is an anthracycline chemotherapeutic agent commonly used for various
types of cancer including breast, ovarian, lung, liver, thyroid and gastric cancers, as well as
different forms of lymphoma, osteocarcinoma, melanoma and leukemia. Doxorubicin is
commercially available in a slightly hydrophilic form with a molecular weight of 581 g/mol.
Upon administration, it rapidly clears from the plasma with a half-life of 3.6 min and is
distributed into tissue [18]. There is a slower clearance from tissue (terminal half-life of - 26.5
h) by clearance and metabolism through the bile duct and kidneys [18]. Doxorubicin acts by
entering cell nuclei and intercalating with DNA, which inhibits RNA and DNA polymerases
[19]. It can also stabilize an intermediate complex between topoisomerase II and DNA. These
in turn lead to the induction of apoptosis or programmed cell death [20]. In addition to being
harmful for any cell in the body that is actively dividing, doxorubicin is specifically and
irreversibly toxic to heart tissue. This is thought to occur due to the formation and accumulation
of reactive oxygen species when doxorubicin interacts with iron in the heart cells. It has been
found that dilative cardiomyopathy and congestive heart failure can develop within one year of
doxorubicin administration. Late forms of cardiac dysfunction can also occur months or years
after therapy [20]. Due to these reasons, the cumulative dose of doxorubicin and other similar
anthracyclines must not exceed 550 mg/m2 for each patient [21]. Conjugating doxorubicin to a
polymer will increase its circulation time in the plasma and reduce uptake into non-target tissue.
Conjugating the polymer-bound doxorubicin to galactose will increase the uptake by cells
expressing the ASGP receptor.
Dextran (poly(a-D-1,6 glucose)) was used as the polymeric carrier to selectively deliver
doxorubicin to hepatocytes. Dextran has many advantages as a drug carrier: it is biocompatible,
inexpensive, and commercially available at various molecular weights. It is FDA-approved and
currently in clinical use for plasma volume expansion, peripheral flow promotion and as an
antithrombolytic agent [22]. Dextran can be cleared from the body by the enzyme dextranase,
which is present in the liver, spleen, kidneys and lower gastrointestinal tract of humans [22].
Dextran has several hydroxyl groups on each glucose unit, which facilitate functionalization by
various methods.
Dextran has been conjugated to or used in the delivery of various chemotherapeutic
agents, anti-inflammatory agents, antibodies, proteins, antibiotics, immunosuppressants and
imaging agents [1, 10, 22-25]. There are several methods that can be used to attach galactose
and doxorubicin onto the dextran backbone for the drug delivery system [9, 23]. Preliminary
synthesis trials were performed, and the periodate oxidation method was chosen due to the
simplicity of this reaction, high yield and ease of characterization. Both doxorubicin and
galactose could be conjugated to dextran through this method. The goal for this study was to
develop a versatile synthesis that could incorporate different targeting moieties and drugs. This
conjugate utilized a highly functional polymer, and conjugated the drug and targeting moiety
through amine groups, which are very common in therapeutics.
2.2 Experimental Methods
2.2.1 Materials
Sodium periodate (NaIO 4), sodium borohydride (NaBH4), galactosamine, calf-thymus
DNA (ct-DNA), doxorubicin and paraformaldehyde were obtained from Sigma-Aldrich.
Dextran with molecular weights of 10, 40 and 170 kilodaltons (kDa) were also obtained from
Sigma-Aldrich. OmniPur 10x phosphate buffered saline (PBS) was used during synthesis at a
1:10 dilution. The cell lines BNL CL.2, NIH/3T3 and H-4-II-E, Dulbecco's Minimum Essential
Medium (DMEM), Eagle's Minimum Essential Medium (EMEM), fetal bovine serum (FBS),
10,000 I.U./mL of Penicillin-10,000 tg/mL of Streptomycin, 0.25% of Trypsin/0.53 mM of
ethylenediaminetetraacetic acid (EDTA), and the MTT Cell Proliferation Assay kit were
obtained from American Type Culture Collection (ATCC). For cell culture studies, Dulbecco's
1 x sterile PBS containing calcium and magnesium was obtained from VWR. The doxorubicin
used for part of this project was a generous donation from Pharmacia & Upjohn (Pfizer).
2.2.2 Synthesis of Targeted Dextran-Doxorubicin-Galactose Conjugates
The synthesis scheme used to attach doxorubicin and galactose to the dextran chain is
shown in Fig. 2.1.
Dissolve dextran in NaIO 4 solution.
Stir in the dark overnight.
Dialyze and lyophilize
Polyaldehyde Dextran (PAD)
Dissolve in PBS
Add doxorubicin, stir overnight.
Add galactosamine, stir overnight.
Reduce with NaBH 4 at 370C, 2 h.
Dialyze and lyophilize
Dextran-Doxorubicin-Galactose (DDG) Conjugate
Fig. 2.1. Schematic of synthesis of targeted dextran-doxorubicin-galactose conjugates.
The conjugate was synthesized as follows. One gram of dextran was dissolved in 100
mL of 0.03 M of NaIO 4 in deionized (DI) water (50% molar ratio of periodate to glucose
groups), and stirred in the dark overnight [26]. The partially activated polyaldehyde dextran
(PAD) was purified by dialysis against 1 L of DI water. The water was changed twice a day over
3 days, and the polymer was recovered by lyophilization. PAD (100 mg) was dissolved in 5 mL
of Ix PBS (pH 7.4), reacted with doxorubicin (10 mg) overnight, and subsequently with
galactosamine (varied amounts) overnight, and reduced with NaBH 4 (12 mg) at 370 C for 2 h.
The resulting dextran-doxorubicin-galactose (DDG) conjugates were dialyzed against 500 mL of
DI water. The water was changed twice a day over 3 days, and the conjugates were recovered by
lyophilization.
The loading of doxorubicin was determined by measuring the absorbance at 485 nm on a
UV-Vis microplate reader (VersaMax, Molecular Devices). The galactose content was
determined from elemental analysis for nitrogen (Atlantic Microlab, Inc.). The presence of
doxorubicin on dextran was verified by 1H nuclear magnetic resonance (NMR) spectroscopy
(Avance DMX 400 MHz, Bruker) in dimethyl sulfoxide (DMSO-d6) (3072 scans). The radius of
gyration of the polymer conjugates was determined by static light scattering (Brookhaven
Instruments Photon Correlation Spectrometer model BI-9000 AT).
2.2.3 Cell-Free Efficacy of Polymer-Bound Doxorubicin
Calf-thymus DNA was dissolved in 1 x PBS (pH 7.4) at a concentration of 1 mg/mL.
Doxorubicin and the polymer conjugates to be tested were also dissolved in 1 x PBS at a
normalized doxorubicin concentration of 12.5 ptg/mL. The assay was carried out in a 96-well
plate by adding 20 ýtL of the doxorubicin or polymer conjugate solution to a final ct-DNA
concentration ranging from 0 to 0.9 mg/mL. Readings were taken on a fluorescence microplate
reader (/Max, Molecular Devices; ex = 488 nm, ,,em = 590 nm) immediately upon addition of the
conjugates [27]. All experiments were performed in triplicate.
2.2.4 In Vitro Efficacy of Polymer Conjugates
The BNL CL.2 (mouse hepatocyte) and NIH/3T3 (mouse fibroblast) cell lines were
cultured in DMEM supplemented with 10% of FBS and 1% of Penicillin-Streptomycin at 370 C
in a 5% CO 2 atmosphere. The H-4-II-E (rat hepatocyte) cell line was cultured in EMEM
supplemented with 10% of FBS and 1% of Penicillin-Streptomycin under identical growth
conditions.
For uptake and cytotoxicity studies, cells were plated in triplicate at 400/mm 2 for the
BNL CL.2 and H-4-II-E cell lines, and at 50/mm2 for the NIH/3T3 cell line in 6-well plates, and
allowed to adhere for 10-14 h. The medium was then replaced with complete medium
containing doxorubicin or polymer conjugates at various concentrations, and incubated for 24 h.
At the end of the experiment, the cell layer was gently washed three times with cold PBS, and
the cells were harvested with Trypsin-EDTA solution and divided into two aliquots to measure
the fluorescence and cell viability. The fluorescence due to the uptake of doxorubicin or
conjugates was evaluated by running an aliquot of the samples through a flow cytometer
(FACScan, Becton Dickinson; FL2-H: Xex = 488 nm, kem = 590 nm). To determine the killing
efficiency, the other aliquot of the cells was replated in 96-well plates, and allowed to adhere for
8-10 h. The medium was replaced with 100 pL of fresh medium and 10 4L of the MTT reagent
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), and the plate was incubated for
1 or 2 h. One hundred microliters of sodium dodecyl sulfate were then added, and the cells were
incubated for another 10 or 12 h. The absorbance was measured at 570 nm. The standard curves
for viable cell numbers were obtained by performing the MTT assay on a known cell
concentration curve, measured by hemacytometer.
Microscopy studies were conducted in chamber slides (Lab-Tek Chambered
Coverglasses, NUNC) using a nominal doxorubicin concentration of 3.6 [M, and incubating for
4, 8 or 24 h. Cells were fixed with 1% of paraformaldehyde solution in lx PBS for 1 h, followed
by 2% of paraformaldehyde for 30 min. Images were obtained with a Zeiss Axiovert 200
Fluorescence Microscope.
2.3 Results and Discussion
2.3.1 Synthesis and Characterization ofPolymer Conjugates
A schematic of the synthesis and structure of the dextran-doxorubicin-galactose
conjugates is shown in Fig. 2.2. The degree of substitution of doxorubicin varied from 1.0% to
2.5%, and that of galactose varied from 3.5% to 11% for conjugates with different molecular
weights. Fig. 2.3 showed the degree of substitution of galactosamine, and Table 2.1 showed the
average degree of substitution of doxorubicin for conjugates at different molecular weights.
Conjugation efficiency based on the amount loaded of each reactant varied from 15% to 54% for
doxorubicin and from 2% to 16% for galactosamine. Fig. 2.4 showed the 'H-NMR spectra of
dextran and DDG at a molecular weight of 170 kDa. The glucosidic protons appeared on the
NMR spectrum in several bands between 3.0 and 5.0 ppm. The following peaks, numbered
according to the molecular structure, were attributed to doxorubicin: (1) methoxy protons at 3.95
ppm, (2) phenyl protons between 6.0 and 8.0 ppm (inset), and (3) phenolic protons at 13.3 and
14.1 ppm (inset). Peaks due to galactosamine could not be distinguished in the NMR spectrum
as they were masked by the glucosidic protons on the dextran backbone.
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Fig. 2.2. Synthesis of the dextran-doxorubicin-galactose conjugates.
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Fig. 2.3. Degree of galactose substitution per glucose monomer for DDG conjugates with
molecular weights of (*) 10 kDa, (*) 40 kDa and (A) 170 kDa. Values are mean ± standard
deviation; n = 3.
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Fig. 2.4. 1H-NMR spectra of (a) dextran and (b) DDG
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Table 2.1. Degree of doxorubicin substitution per glucose monomer for DDG conjugates with
the molecular weights indicated. Values are mean ± standard deviation; n = 3.
Molecular Weight (kDa) Doxorubicin (mol%)
10 1.2 ± 0.2
40 1.5 ± 0.1
170 1.5 ± 0.2
Periodate oxidation of the dextran hydroxyl groups was used to attach both doxorubicin
and galactose to the polymer chain. Only 50% of the glucose groups were activated so as to
maintain the water-solubility of the conjugates. The aldehyde groups on PAD reacted with the
primary amines on doxorubicin and galactosamine to form imine bonds, which were reduced
with NaBH4 to form amine bonds. The reactions with doxorubicin and galactosamine were
performed in two different steps to ensure relatively constant doxorubicin substitution for varied
galactose substitutions. Simultaneous reaction would have resulted in decreasing doxorubicin
substitution with increasing galactosamine introduced. In this case, increasing the amount of
doxorubicin added to the reaction mixture would have raised the degree of substitution of
doxorubicin slightly, but would result in a low reaction efficiency of 1-15%. Thus, the two-step
reaction was preferred since it maintained a relatively constant degree of substitution of
doxorubicin, while improving the substitution efficiency significantly. The dextran-doxorubicin
conjugates were identified as DD followed by the molecular weights, while the DDG conjugates
were designated with the molecular weights and degrees of galactose substitution. For example,
DDG 40 kDa 6.9 referred to a DDG conjugate with 40 kDa molecular weight and 6.9 mol%
galactose substitution.
2.3.2 Cell-Free Testing ofPolymer-Bound Doxorubicin
Doxorubicin acted by entering the nuclei of cells and intercalating with the DNA. A
fluorescence-based cell-free assay was used to examine if the dextran-bound doxorubicin
remained effective [27]. When doxorubicin was bound to DNA, its fluorescence would be
quenched. The degree of fluorescence quenching (F/Fo) at a particular DNA concentration was
determined by taking the ratio of that fluorescence reading (F) to the reading in the absence of
DNA (Fo). The assay indicated that all our conjugates intercalated with DNA. As seen in Fig.
2.5, conjugates with various molecular weights and galactose substitutions exhibited
fluorescence quenching, though not to the same extent as free doxorubicin. The extent of
quenching increased with the polymer molecular weight. The conjugates with a molecular
weight of 170 kDa could undergo almost complete quenching, whereas those with molecular
weights of 10 kDa and 40 kDa showed at most ~ 50% quenching. The fluorescence quenching
also decreased slightly with galactose substitution at 170 kDa. The doxorubicin substitutions for
the conjugates are shown in Table 2.2.
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Fig. 2.5. Fluorescence quenching of doxorubicin in the presence of ct-DNA for (.) doxorubicin,
(x) DD 10 kDa, (A) DD 40 kDa, (m) DD 170 kDa, (o) DDG 170 kDa 7.4, and (e) DDG 170 kDa
10.4. Values are mean ±- standard deviation; n = 3.
It has been shown that when doxorubicin intercalates with double-stranded DNA, the
DNA "buckles" into a distorted helix. This distorted structure is stabilized by a number of
electrostatic interactions, including hydrogen bonding between the hydrogen on the amino sugar
on doxorubicin and a thiamine base in the minor groove of DNA [28]. The reduction observed
in the fluorescence quenching of the conjugates compared to that of doxorubicin was attributed
partly to the occupation of the amine group in the synthesis reaction. Additional effect observed
with conjugates of low molecular weights might be due to the reduced degrees of substitution of
doxorubicin (see Table 2.2). To achieve a normalized doxorubicin concentration, it was
necessary to use a greater mass of the lower molecular weight polymers. Consequently, there
was more polymer in solution to interfere with the binding between doxorubicin and DNA. In
contrast, all of the conjugates with 170 kDa molecular weight achieved close to 100% quenching
in spite of having varying doxorubicin substitutions. They carried a significantly larger number
of doxorubicin molecules on each polymer chain as compared to the conjugates with 10 kDa and
40 kDa molecular weights. The proximity of the doxorubicin molecules on the same polymer
chain might have also contributed to the higher degree of fluorescence quenching in the former.
Once one doxorubicin molecule intercalated with DNA, the remaining molecules on the same
polymer chain were brought into the immediate vicinity of the DNA and were more likely to be
bound, resulting in greater fluorescence quenching.
Table 2.2. Degree of substitution and number of doxorubicin molecules per polymer chain for
conjugates in Fig. 2.5.
Galactose Doxorubicin
(kDMolecular Weight Substitution Substitution Doxorubicin/Polymer Chain
(mol%) (mol%)
10 0 1.7 1
40 0 1.9 5
170 0 2.1 26
170 7.3 1.4 15
170 10.4 1.7 18
2.3.3 In Vitro Studies
Table 2.3 lists the polymer conjugates used for the in vitro experiments. The amount of
conjugate added was normalized in doxorubicin content for these experiments.
2.3.3.1 Uptake ofDoxorubicin in the BNL CL.2 Cell Line
Flow cytometry was used to determine the excess fluorescence of cells incubated with
either doxorubicin or conjugates. Floating cellular debris or dead cells were removed from the
media during sample preparation for flow cytometry. Cells were gated according to light
scattering parameters to isolate the live cell population. A slight shift in side scatter was
observed for cells treated with some of the conjugates. The histogram profiles for all
experiments were almost exclusively unimodal. Fig. 2.6 shows the histograms obtained from the
FACScan FL2-H detector for several uptake experiments. It was found that the fluorescence of
cells increased as the doxorubicin content was increased in the experiments.
Table 2.3. Conjugates used in in vitro studies.
Molecular Weight Doxorubicin Substitution Galactose Substitution
Sample(kDa) (mol%) (mol%)
1 10 1.1 0
2 10 1.4 3.7
3 10 1.2 5.6
4 10 1.3 7.6
5 40 1.5 0
6 40 1.4 5.5
7 40 1.5 6.9
8 40 1.7 10.2
9 170 1.6 0
10 170 1.4 5.4
11 170 1.4 7.3
12 170 1.7 10.4
100 101 102 103  104
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Fig. 2.6. Doxorubicin-associated fluorescence of BNL CL.2 cells incubated for 24 h with (a) no
treatment, and DDG 170 kDa conjugates with galactose substitutions of (b) 0, (c) 5.4, (d) 7.3 and
(e) 10.4 mol% at a nominal doxorubicin concentration of 9 riM.
Figs. 2.7-2.10 show the ratio of the fluorescence of BNL CL.2 cells incubated with
doxorubicin or conjugates to the fluorescence of untreated cells. Fig. 2.7 indicates that the
uptake of free doxorubicin was much higher than the uptake of the conjugates, which appeared to
approach a plateau as doxorubicin content in the cell incubation medium was increased. Since
there was less association with the polymer conjugates than with doxorubicin, the conjugates
were expected to have less non-specific toxicity than free doxorubicin.
Fig. 2.7 also illustrates that the uptake of doxorubicin increased for higher molecular
weight polymers. As mentioned previously, the chain loading of doxorubicin increased with the
conjugate's molecular weight (see Table 2.2). Therefore, if one molecule of the 170 kDa
polymer entered the cell, it increased the fluorescence to a much greater extent than the 10 kDa
polymer.
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Fig. 2.7. Doxorubicin-associated fluorescence ratio of BNL CL.2 cells incubated for 24 h with
(A) doxorubicin, and DD conjugates with molecular weights of (*) 10 kDa, (x) 40 kDa and (.)
170 kDa. Values are mean + standard deviation; n = 3.
The doxorubicin uptake also increased with the degree of substitution of galactose for
conjugates of all molecular weights (see Figs. 2.8-2.10). BNL CL.2 cells are known to express a
high concentration of the ASGP receptor on the surface [29-32], and a higher degree of
substitution of galactose on the conjugates would be expected to increase the cell uptake.
1000
0 10 20 30
Doxorubicin Dose (lpM)
Fig. 2.8. Doxorubicin-associated fluorescence ratio of BNL CL.2 cells incubated for 24 h with
(+) doxorubicin, and DDG 10 kDa conjugates with galactose substitutions of (.) 0, (x) 3.7, (i)
6.7 and (A) 7.6 mol%. Values are mean ± standard deviation; n = 3.
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Fig. 2.9. Doxorubicin-associated fluorescence ratio of BNL CL.2 cells incubated for 24 h with
(*) doxorubicin, and DDG 40 kDa conjugates with galactose substitutions of (e) 0, (x) 5.5, (n)
6.9 and (A) 10.2 mol%. Values are mean ± standard deviation; n = 3.
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Fig. 2.10. Doxorubicin-associated fluorescence ratio of BNL CL.2 cells incubated for 24 h with
(*) doxorubicin, and DDG 170 kDa conjugates with galactose substitutions of (e) 0, (x) 5.4, (i)
7.3 and (A) 10.4 mol%. Values are mean + standard deviation; n = 3.
2.3.3.2 Cytotoxicity Studies on the BNL CL.2 Cell Line
Cell viability was measured using the MTT assay, which is a standard colorimetric assay
for measuring cell proliferation. The MTT tetrazolium salt was reduced to insoluble, purple
formazan crystals in the mitochondria of cells. The crystals were solubilized with sodium
dodecyl sulfate, and the amount was quantified by measuring absorbance. The amount of
precipitate formed was directly proportional to the number of living cells, which with regard to
this assay was defined as cells that were metabolically active. Even though the MTT assay did
not provide a direct measure of the action of doxorubicin, it was employed since it was a simple
and rapid method for quantifying cell viability.
The concentration corresponding to 50% of cell death (LC 5o) was determined from the
slope and intercept of the straight line obtained by inverting the dose vs. cell death data from the
cytotoxicity studies. The LC50 values obtained by this method were corroborated by
determination with a logistic model, as well as visual confirmation from the dose-response
curves.
Cytotoxicity profiles of the polymer conjugates corresponded well with the trends
observed for cell uptake. Fig. 2.11 showed the dose response curve of doxorubicin and non-
targeted DD conjugates with different molecular weights. All the polymer conjugates were less
toxic to cells than free doxorubicin. The LC50 for DD 10 kDa was 36.4 jiM, which was much
higher than that for free doxorubicin (1.8 pM). The toxicity was higher for conjugates with
higher molecular weights. The LC 50 values for DD 40 kDa and DD 170 kDa were 30.9 and 25.6
jM, respectively (see Table 2.4).
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Fig. 2.11. Dose response curves of BNL CL.2 cells incubated for 24 h with (A) doxorubicin, and
DD conjugates with molecular weights of (o) 10 kDa, (x) 40 kDa and (.) 170 kDa. Values are
mean + standard deviation; n = 3.
The DD conjugates were much less toxic than free doxorubicin for a number of reasons.
There was less uptake of doxorubicin in its polymer-bound form at the same concentration as
shown in Figs. 2.7-2.10. Additionally, after internalization, the conjugates needed to enter the
nucleus to cause cell death. Proteins or metabolites of up to 40 kDa can passively enter the
nucleus through the nuclear pore complex (NPC) in mammalian cells, and the NPC transport
channel can dilate up to 40 nm in response to certain cellular signals [33]. Our DD conjugates
with molecular weights of 10 kDa and 40 kDa were small enough for individual polymer chains
to have passively diffused into the nucleus. However, these conjugates carried a lower chain
loading of doxorubicin than DD 170 kDa. Also, according to static light scattering
measurements, the radius of gyration of the conjugates ranged from 15 nm to 40 nm, indicating
that the conjugates might have aggregated into larger structures. This implied that DD 10 kDa
and DD 40 kDa did not have a size advantage in terms of nuclear uptake. Another possible
reason for the lower toxicity of the DD conjugates could be their less effective intercalation to
DNA as compared to free doxorubicin (Fig. 2.5).
Table 2.4. LC50 of DD and DDG conjugates in BNL CL.2 cells.
MW = 10 kDa MW = 40 kDa MW = 170 kDa
LC5o LC50 LC5oDrug Drug Drug
DD 36.4 DD 30.9 DD 25.6
DDG 3.7 33.3 DDG 5.5 24.7 DDG 5.4 18.6
DDG 6.7 25.4 DDG 6.9 15.5 DDG 7.3 13.1
DDG 7.6 21.2 DDG 10.2 10.1 DDG 10.4 8.6
Targeted conjugates were significantly more toxic than the non-targeted conjugates of the
same molecular weight (Table 2.4 and Figs. 2.12-2.14). The toxicity of the conjugates increased
with an increase in the degree of galactose substitution for all three molecular weights. DDG 170
kDa 10.4 has a particularly low LC 50 value of 8.6 VlM.
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Fig. 2.12. Dose response curves of BNL CL.2 cells incubated for 24 h
DDG 10 kDa conjugates with galactose substitutions of (e) 0, (x) 3.7,
Values are mean ± standard deviation; n = 3.
with (+) doxorubicin, and
(m) 6.7 and (A) 7.6 mol%.
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Fig. 2.13. Dose response curves of BNL CL.2 cells incubated for 24 h with (+) doxorubicin, and
DDG 40 kDa conjugates with galactose substitutions of (.) 0, (x) 5.5, (m) 6.9 and (A) 10.2 mol%.
Values are mean ± standard deviation; n = 3.
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Fig. 2.14. Dose response curves of BNL CL.2 cells incubated for 24 h with (*) doxorubicin, and
DDG 170 kDa conjugates with galactose substitutions of (.) 0, (x) 5.4, (m) 7.3 and (&) 10.4
mol%. Values are mean ± standard deviation; n = 3.
Fig. 2.15 shows the light and fluorescence micrographs of hepatocytes incubated with
doxorubicin and DDG 170 kDa 10.4. The free doxorubicin was localized almost exclusively in
the nuclei of cells. In contrast, DDG 170 kDa 10.4 was found throughout the entire cell, with
localization occurring outside the nucleus as well. More localization in the nuclei was observed
after incubating the cells with polymer conjugates for 24 h.
Fig. 2.15. Light (left) and fluorescence (right) micrographs of BNL CL.2 cells incubated with
(a,b) doxorubicin for 8 h, and DDG 170 kDa 10.4 for (c,d) 8 h and (e,f) 24 h at a nominal
doxorubicin concentration of 3.6 ýpM. Scale bar = 25 gtm. Nuclei were marked with arrows on
the light micrographs.
2.3.3.3 Uptake ofDoxorubicin in the Control Cell Line
The uptake of doxorubicin and polymer conjugates was also determined in the NIH/3T3
cell line, which are mouse fibroblasts with no specificity for galactose uptake. Fig. 2.16 shows
that doxorubicin uptake was significantly higher than the uptake of the DD conjugates. There
was greater uptake of the DD conjugates of increasing molecular weights, as was observed also
for the BNL CL.2 cell line. Fig. 2.17 shows the uptake of DDG 170 kDa conjugates with
different galactose substitutions. As expected, the uptake of the conjugates in the NIH/3T3 cell
line was not affected by the degree of substitution of galactose.
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Fig. 2.16. Doxorubicin-associated fluorescence ratio of NIH/3T3 cells incubated for 24 h with
(A) doxorubicin, and DD conjugates with molecular weights of (e) 10 kDa, (x) 40 kDa and (.)
170 kDa. Values are mean ± standard deviation; n = 3.
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Fig. 2.17. Doxorubicin-associated fluorescence ratio of NIH/3T3 cells incubated for 24 h with
(+) doxorubicin, and DD 170 kDa conjugates with galactose substitutions of (e) 0, (x) 5.4, (M) 7.3
and (A) 10.4 mol%. Values are mean ± standard deviation; n = 3.
2.3.3.4 Cytotoxicity Studies in the Control Cell Lines
The cytotoxicity trends followed the uptake profiles for the NIH/3T3 cell line. There was
a slight decrease in the LC 50o with increasing molecular weight of polymer (see Fig. 2.18 and
Table 2.5). Fig. 2.19 shows that there was negligible difference in LC 5o due to the degree of
substitution of galactose.
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Fig. 2.18. Dose response curve of NIH/3T3 cells incubated for 24 h with (A) doxorubicin, and
DD conjugates with molecular weights of (e) 10 kDa, (x) 40 kDa and (*) 170 kDa. Values are
mean ± standard deviation; n = 3.
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Fig. 2.19. Dose response curve of NIH/3T3 cells incubated for 24 h
DDG 170 kDa conjugates with galactose substitutions of (e) 0, (x)
mol%. Values are mean ± standard deviation; n = 3.
with (*)
5.4, (m)
doxorubicin, and
7.3 and (A) 10.4
The cytotoxicity of DDG conjugates was also tested in H-4-II-E, a rat hepatocyte cell line
that has a low expression of galactose binding sites (< 5000 galactose binding sites per cell) [34].
In this cell line, the degree of substitution of galactose also had no effect on the LC5o (see Fig.
2.20 and Table 2.6).
Table 2.5. LC5 0 of doxorubicin, DD and DDG conjugates in NIH/3T3 cells.
Drug LC 50 (PM)
Doxorubicin 0.37
DD 10 kDa 10.7
DD 40 kDa 9.0
DD 170 kDa 7.4
DDG 170 kDa 5.4 7.7
DDG 170 kDa 7.3 7.4
DDG 170 kDa 10.4 7.5
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Fig. 2.20. Dose response curve of H-4-II-E cells incubated for 24 h with (A) doxorubicin, and
DDG 170 kDa conjugates with galactose substitutions of (e) 0, (m) 4.5 and (.) 7.7 mol%. Values
are mean ± standard deviation; n = 3.
Table 2.6. LCso of doxorubicin, DD and DDG conjugates in H-4-II-E cells.
Drug LC 5o ([tM)
Doxorubicin 5.0
DD 170 kDa 47.1
DDG 170 kDa 4.5 47.1
DDG 170 kDa 7.7 52.6
2.3.4 Effect of Galactose Substitution on LC5so in Target and Control Cell Lines
Fig. 2.21 demonstrates the reduction in LC50 achieved with galactose substitution on the
target BNL CL.2 cells. The ratio of the LCso for a DDG conjugate to that for the untargeted DD
conjugate with the same molecular weight were plotted against the galactose substitution. With
galactose substitution, the dose of doxorubicin needed to achieve the same cytotoxic effect was
reduced by as much as 42% for DDG 10 kDa, and by as much as 66% for DDG 40 kDa and
DDG 170 kDa. The normalized reductions observed for the DDG conjugates of different
molecular weights were quite similar at a given degree of galactose substitution.
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The ratio of the LCso for DDG 170 kDa conjugates to that for the DD 170 kDa conjugate
was also compared for the three different cell lines. Fig. 2.22 illustrates that the galactose
substitution had no effect on the LC50 of DDG 170 kDa for the control NIH/3T3 and H-4-II-E
cell lines. Increasing galactose substitution only gave rise to significant reduction in the LC5o for
DDG 170 kDa on the BNL CL.2 cells. This confirmed the successful targeting of BNL CL.2
cells by DDG conjugates, which were taken up by receptor-mediated endocytosis through the
ASGP receptors in the BNL CL.2 cell line.
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Fig. 2.22. Change in LC5o on (o) BNL CL.2, (m) NIH/3T3 and (A) H-4-II-E cells incubated for 24
h with DDG 170 kDa conjugates, as a function of galactose substitution.
2.4 Summary
Doxorubicin and dextran have been prepared as polymer conjugates of different
molecular weights, and different degrees of galactose substitution have been introduced to target
hepatocytes. The degree of doxorubicin substitution was maintained by performing the
doxorubicin conjugation and galactose conjugation in two sequential steps. The synthesis
scheme was simple, efficient and easily adaptable to other therapeutic agents and targeting
moieties with free amine groups.
In cell culture studies on the target cell line, the DDG conjugates showed lower toxicity
compared to doxorubicin, increased toxicity with higher molecular weight polymers, and greater
toxicity with higher degree of galactose substitution. Experiments in the control cell lines
showed increased toxicity for higher molecular weight polymers; however, there was no effect
due to the presence of galactose.
At diameters of 15-40 nm, the polymer conjugates were too large to enter the cell nuclei
in large quantities, but sufficient conjugates entered the nuclei to cause cell death. The higher
molecular weight polymers were more effective since they carried more doxorubicin molecules
per polymer chain.
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Chapter 3 - Synthesis, Characterization and In Vitro Studies of Acid-Labile Dextran
Conjugates for Doxorubicin Delivery
3.1 Introduction
When a drug is delivered as a conjugate with a polymer, an antibody or other
macromolecule, it may have lower efficacy or a different mechanism of action compared to the
free drug. Release or activation of the drug may be necessary to achieve the required effect.
Hovorka et al. have demonstrated that doxorubicin stably conjugated to poly((N-2-
hydroxypropyl)methacrylamide) (HPMA) has a different mechanism of action from free
doxorubicin [1]. Free doxorubicin intercalated with nuclear and mitochondrial DNA, causing
single- and double-stranded breaks, which started a cascade of signaling leading to apoptosis.
Conversely, the HPMA-bound doxorubicin caused cell death mainly by necrosis and other
cytocidal effects. Doxorubicin was not detected in the nucleus even after 72 h.
In Chapter 2, we synthesized a dextran-doxorubicin-galactose conjugate that was
successful at targeting hepatocytes [2]. We did observe some nuclear localization of the
conjugate even after only 8 h, and were able to observe an increase by 24 h. In cell-free buffer,
the polymer had a very slight effect on the ability of doxorubicin to intercalate with DNA due to
the occupation of the amino sugar group of doxorubicin. However, the cytotoxicity was limited
since the size of the polymer conjugates reduced the nuclear uptake. The LC5 0 of the most toxic
conjugate was 8.6 gM, compared to 1.8 ýiM for free doxorubicin. Therefore, a drug delivery
vehicle that releases free doxorubicin inside the cell would be more effective.
Several methods for drug release have been investigated, which involved temperature-
sensitive, membrane-disruptive, acid-labile and enzyme-degradable materials. Polymers of N-
isopropylacrylamide (NIPAAm) are often used in micelles, liposomes and hydrogels for their
temperature-sensitive behavior [3, 4]. Skirtach et al. have synthesized thermo-responsive
polyelectrolyte multilayered shells doped with metal nanoparticles, which disrupted the
membrane and led to release when treated with near infrared laser [5]. Hydrocarbon chains have
also been utilized as membrane disruptive agents. Kyriakides et al. have synthesized
poly(propylacrylic acid) (PPAA), which was effective at membrane disruption at a pH below 6.5,
and tested it in in vitro studies and an in vivo excisional wound healing model. The propyl group
acted as a hydrophobic membrane destabilizer. They have also demonstrated the delivery of
green fluorescent protein (GFP) in cell culture studies [6]. Doxorubicin and daunorubicin have
been conjugated to human serum albumin or transferrin with a disulfide bond, which was
reduced inside the cell to release the free drug. Over 50% of the conjugated drug was released
within 24 h, and in vivo experiments have shown promising results [7]. Doxorubicin has also
been conjugated to HPMA with enzymatically degradable peptide linkers, as well as acid-labile
bonds [8-10]. In general, pH-sensitive release has been shown to be more toxic in cell culture
studies than peptide-cleavable conjugates [7, 11].
In pH-responsive drug delivery, research has been conducted on polymer conjugates,
hydrogels, particles, micelles, dendrimers and liposomes [12-22]. Polymers that have been used
to form pH-sensitive conjugates included dextran, alginic acid, carboxymethyl cellulose,
poly(amino acids), HPMA and poly(ethylene glycol) (PEG) [7]. Murthy et al. have synthesized
"encrypted polymers" that mimicked the multi-functional design of biology. Their membrane-
disruptive polymer was protected with pendant PEG groups attached with disulfide bonds.
These bonds were reduced at low pH's and the PEG groups would dissociate from the polymer,
which escaped from the endosome by disrupting the membrane [17]. Chiu et al. have attached
acrylic acid to dextran to make it pH-sensitive for application in colon cancer treatment [20].
Yessine et al. have synthesized a NIPAAm copolymer with poly(methacrylic acid) and octadecyl
acrylate. This formed a polyanion that changed from a coil to a globule conformation in acidic
conditions; it was used to synthesize pH-sensitive liposomes that could escape from the
endosome [21].
Carboxylic hydrazone, cis-aconityl and acetal are common acid-labile bonds that have
been investigated extensively for use in drug delivery. Imine and ketal bonds have also been
studied to a lesser extent [7, 10, 23]. The cis-aconityl bond has been utilized to form
nanoaggregates between glycol and chitosan to deliver doxorubicin. About 20% of the drug was
released from the delivery vehicle after 8 days. The aggregates had an average size of 250 nm,
and were found to be retained in tumors in in vivo studies due to the enhanced permeability and
retention (EPR) effect. There was also significant accumulation in the kidneys since the
aggregates were not targeted to the tumors [24]. Some researchers have shown that the
hydrazone bond was more effective than the cis-aconityl bond in cell culture experiments [9, 11].
One inherent disadvantage of using cis-aconityl was that the pendant cis-aconityl moiety could
be lost in the side reactions, causing the drug conjugate to be less sensitive to pH [11]. Yoo et al.
have conjugated doxorubicin to a copolymer of poly(lactic acid) and methoxy-PEG with acetal
and hydrazone bonds. The micelles formed from the hydrazone-linked doxorubicin conjugate
had higher overall release and greater cytotoxicity in cell culture studies [12].
A pH-sensitive dextran-doxorubicin conjugate would be more cytotoxic since it would
release the drug in a free form. Also, due to the EPR effect, drug conjugates would tend to
accumulate in tumors, and a pH-sensitive conjugate would release the drug inside the tumor [7].
Therefore, in addition to greater efficacy after cellular delivery, the pH-sensitive conjugates
would also potentially be helpful specifically in treating tumors. The goal for this study was to
attach doxorubicin to dextran in a pH-sensitive manner so that the drug would be released at a
low pH. The hydrazone bond was chosen since it showed the most promising results in the
literature.
3.2 Experimental Methods
3.2.1 Materials
Anhydrous dimethylformamide (DMF), anhydrous dimethylsulfoxide (DMSO), lithium
chloride (LiC1), pyridine, 4-nitrophenylchloroformate (NPC), hydrazine, doxorubicin and bovine
serum albumin (BSA) were obtained from Sigma-Aldrich. Dextran at molecular weights
(MW's) of 10, 40, 70 and 170 kilodaltons (kDa) were also obtained from Sigma-Aldrich.
OmniPur 10x phosphate buffered saline (PBS) was used during synthesis at a 1:10 dilution.
Ethanol and diethyl ether and Dulbecco's 1 x sterile PBS containing calcium and magnesium for
cell culture studies were obtained from VWR. The murine hepatocytic cell line BNL CL.2,
Dulbecco's Minimum Essential Medium (DMEM), fetal bovine serum (FBS), Penicillin-
Streptomycin, 0.25% of Trypsin/0.53 mM of ethylenediaminetetraacetic acid (EDTA), and the
MTT Cell Proliferation Assay kit were obtained from American Type Culture Collection
(ATCC). LysoTracker Green, SYBR Green Nucleic Acid Stain, RNase A and propidium iodide
(PI) were obtained from Invitrogen. Macro Fast DispoDialyzer cassettes (Harvard Apparatus)
were used with a molecular weight cut-off (MWCO) of 5 kDa.
3.2.2 Synthesis ofAcid-Labile Dextran-Hydrazone-Doxorubicin Conjugates
The synthesis scheme used to attach doxorubicin to the dextran chain with a pH-sensitive
hydrazone bond is shown in Fig. 3.1. Dextran was activated with NPC following the method
given by Ramirez et al. [25]. The reaction was performed in a dry nitrogen atmosphere, and the
reagents were prepared as follows. Dextran was dried under vacuum at 100 0 C overnight. NPC
was also dried under vacuum at room temperature overnight. A solution of 20 g/L of LiCl in
DMF was purged with nitrogen overnight. In the first step, 1 g of vacuum dried dextran was
dissolved in 100 mL of LiCl/DMF at 900 C. After the dextran had dissolved, the solution was
transferred to an ice bath, and 0.5 g of pyridine and 1.2 g of NPC (both equimolar to glucose
residues on dextran) were added. The reaction solution was kept in an ice bath for 4 h, and the
resulting nitrophenyl carbonate-dextran was precipitated in a 4:1 volume mixture of ethanol and
diethyl ether. The product was centrifuged, washed two more times with a 4:1 volume mixture
of ethanol and diethyl ether, and dried under vacuum. The presence of the nitrophenyl group on
dextran was confirmed by nuclear magnetic resonance (NMR) spectroscopy (Avance DMX 400
MHz, Bruker) in dimethyl sulfoxide (DMSO-d6) and photoacoustic Fourier-transform infrared
(PA-FTIR) spectroscopy (Bio-Rad FTS60A).
1 g of the synthesized nitrophenyl carbonate-dextran was dissolved in 25 mL of
anhydrous DMSO, and reacted with 2.0 g (1Ox molar ratio to glucose residues on dextran) of
hydrazine [26]. The reaction was allowed to proceed for 3 h, and the dextran-hydrazide was
purified by dialysis against 1 L of deionized (DI) water. The dialysis water was changed twice a
day for three days. Dextran-hydrazide was recovered by lyophilization, and was characterized
by NMR and PA-FTIR spectroscopies for the disappearance of the nitrophenyl carbonate group.
In the final step, 100 mg of dextran-hydrazide were dissolved in 5 mL of lx PBS (pH
7.4). Doxorubicin (10 mg) and 1 drop of glacial acetic acid were added, and allowed to react for
48 h. The final dextran-hydrazone-doxorubicin (DHD) conjugate was purified by dialysis
against 500 mL of 1 x PBS (pH 7.4). The PBS was changed twice a day for three days, and the
polymer conjugate was recovered by lyophilization. The degree of substitution of doxorubicin
was determined by measuring the absorbance at 485 nm on a UV-Vis microplate reader
(VersaMax, Molecular Devices).
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of LiC1/DMF at 90*C
Pyridine - React with NPC. Stir in ice bath, 4 h
Precipitate and dry
Nitrophenyl Carbonate-Dextran
Dissolve in DMSO
React with hydrazine, 3 h
Dialyze and lyophilize
Dextran-Hydrazide
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Dextran-Hydrazone-Doxorubicin
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Fig. 3.1. Schematic of synthesis of dextran-hydrazone-doxorubicin conjugate.
3.2.3 Cell-Free Efficacy of Dextran-Hydrazone-Doxorubicin Conjugates
Calf-thymus DNA was dissolved in 1 x PBS (pH 7.4) at a concentration of 1 mg/mL.
Doxorubicin and the polymer conjugates to be tested were also dissolved in 1 x PBS at a
normalized concentration of 12.5 ~g/mL of doxorubicin. The assay was performed in a 96-well
plate by adding 20 gtL of the doxorubicin or polymer conjugate solution to a final ct-DNA
concentration ranging from 0 to 0.9 mg/mL. Readings were taken on a fluorescence microplate
reader (/Max, Molecular Devices; ,ex = 488 nm, Xem = 590 nm) immediately upon addition of
conjugates [27]. All experiments were performed in triplicate.
3.2.4 Doxorubicin Release from Acid-Labile Conjugates
The release of doxorubicin from the acid-labile DHD conjugate was tested in 0.1 M of
sodium acetate buffer with 0.05 M of sodium chloride at pH's of 7.4 and 5.0. The DHD
conjugates were dissolved in each buffer, transferred to a Macro Fast DispoDialyzer cassette,
immersed in 5 mL of the buffers, and incubated at 370 C. At each time point, 0.75 mL of the
dialysate was removed for analysis, and replaced with fresh buffer. Release was observed over
24 h. The amount of doxorubicin released was determined by measuring absorbance at 485 nm.
3.2.5 In Vitro Efficacy of Polymer Conjugates
The BNL CL.2 cell line was cultured in DMEM supplemented with 10% FBS and 1%
Penicillin-Streptomycin at 370 C in 5% of CO2.
For uptake and cytotoxicity studies, cells were plated at 400/mm 2 in six-well plates, and
allowed to adhere for 10-14 h. The medium was then replaced with complete medium
containing doxorubicin or polymer conjugates at various concentrations, and incubated for 24 h.
At the end of the experiment, the cell layer was gently washed three times with cold PBS, and
cells were harvested with Trypsin-EDTA. The fluorescence due to the uptake of doxorubicin or
conjugates was evaluated by running the cell samples through a flow cytometer (Becton
Dickinson FACScan, FL2-H; Xex = 488 nm, kem = 590 nm). All experiments were performed in
triplicate.
To determine the killing efficiency, the harvested cells described in the preceding
paragraph were replated in 96-well plates, and allowed to adhere for 8-10 h. The medium was
replaced with 100 ýpL of fresh medium and 10 ýpL of the MTT reagent (3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide), and the plate was incubated for 1 or 2 h. 100 jiL of
sodium dodecyl sulfate were then added, and the cells were incubated for another 10 or 12 h.
The absorbance was measured at 570 nm. The standard curves for cell viability were obtained
by performing the MTT assay on a known cell concentration curve, measured by
hemacytometer.
The DNA content of the treated cells was analyzed by flow cytometry. Cells were treated
with doxorubicin or conjugates for 24 h at a nominal doxorubicin concentration of 3.6 [M. The
cells were then harvested, washed twice with lx PBS, redispersed in PBS, and fixed in cold
ethanol overnight at 4°C. After fixation, the cells were washed twice with PBS containing 1%
BSA, redispersed in the PBS solution, and PI and RNase were added to yield final concentrations
of 50 gg/mL and 1 mg/mL, respectively. The cells were incubated at 370 C for 30 min and
analyzed by flow cytometry.
The uptake of the conjugates was observed by performing live cell microscopy on a Zeiss
LSM510 laser scanning confocal microscope. Cells were plated at 400/mm2 in chambered slides
(Lab-Tek Chambered Coverglasses, NUNC), and allowed to adhere for 10-14 h. LysoTracker
Green was diluted in complete cell culture medium to a concentration of 100 nM, and used to
stain the acidic intracellular vesicles. Cells were incubated with LysoTracker for 30 min at
370 C. The slides were placed in a temperature-, humidity- and CO2-controlled chamber, and the
images were obtained at 10-min intervals immediately after addition of free doxorubicin or
conjugates at a nominal doxorubicin concentration of 9.0 gM.
Cells incubated with doxorubicin (nominal concentration = 3.6 gM) were fixed in
paraformaldehyde, the nuclei were counterstained with SYBR Green, and confocal images were
obtained after incubation for 4 or 8 h.
3.3 Results and Discussion
3.3.1 Synthesis and Characterization of Polymer Conjugates
A schematic of the reaction to form dextran-hydrazone-doxorubicin conjugates was
shown in Fig. 3.2. The structure of nitrophenyl carbonate-dextran was confirmed by 'H NMR
and PA-FTIR spectra (Figs. 3.3 and 3.4). The glucosidic protons appeared on the NMR
spectrum in several bands between 3.0 and 5.5 ppm. For nitrophenyl carbonate-dextran (Fig.
3.3(b)), the peaks from 7.5 to 8.5 ppm were attributed to the protons on the phenyl group. The
nitrophenyl carbonate group was replaced during the reaction with hydrazine, as confirmed by
the disappearance of the phenyl protons from the NMR spectrum of dextran-hydrazide (Fig.
3.3(c)). The final DHD conjugate (Fig. 3.3(d)) exhibited peaks due to phenyl protons between
6.5 to 7.8 ppm. The carbonate on nitrophenyl carbonate-dextran (Fig. 3.4(b)) showed a
characteristic FTIR peak at 1770 cm-', which was not observed for dextran-hydrazide (Fig.
3.4(c)). The degrees of substitution of doxorubicin on conjugates of various MW's are listed in
Table 3.1. This was controlled by the amount of doxorubicin added during the reaction, and did
not increase significantly above 2.0 mol%. The efficiency of doxorubicin conjugation was
between 5% and 8% for the different MW's.
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Fig. 3.2. Synthesis of the dextran-hydrazone-doxorubicin conjugates.
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Fig. 3.3. 1H NMR spectra of (a) dextran, (b) nitrophenyl carbonate-dextran, (c) dextran-
hydrazide and (d) DHD with a MW of 10 kDa.
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Fig. 3.4. PA-FTIR spectra of (a) dextran, (b) nitrophenyl carbonate-dextran and (c) dextran-
hydrazide with a MW of 10 kDa.
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Table 3.1. Degree of doxorubicin substitution per glucose monomer for DHD conjugates with
various MW's. Values are mean ± standard deviation; n = 2.
Conjugate Molecular Doxorubicin
Weight (kDa) (mol%)
10 1.9 ± 0.2
40 1.9 ± 0.2
70 1.1 ± 0.9
170 1.1 ± 0.2
3.3.2 Cell-Free Testing of DHD Conjugates
3.3.2.1 DNA Binding Studies
The efficacy of doxorubicin can be lowered when it is bound to
released in an altered form. Therefore, the DNA binding efficiency of
conjugates and the doxorubicin released from the conjugates were
fluorescence-based assay.
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Fig. 3.5. Fluorescence quenching of doxorubicin in the presence of ct-DNA for (x) doxorubicin,
DHD conjugates of MW's of (.) 10 kDa, (e) 40 kDa, (m) 70 kDa and (A) 170 kDa, and (o)
doxorubicin released from DHD 10 kDa. Values are mean ± standard deviation; n = 3.
The acid-labile DHD conjugates showed a significant degree of binding with ctDNA
(Fig. 3.5). There was no clear trend in the effect of MW of the conjugates on the degree of
binding. It has been shown that the chromophore and amino-sugar groups of doxorubicin were
involved in the intercalation with DNA [28]. In this case, the acetyl group of doxorubicin was
occupied in the formation of the DHD conjugates. Since both of the DNA binding sites were
free, a significantly improved degree of interaction was observed as compared to the previously
synthesized dextran-doxorubicin (DD) conjugates [2]. Fig. 3.5 also shows the efficacy of
doxorubicin that has been released from the 10 kDa conjugate at 370 C and a pH of 5.0.
Fluorescence quenching of the released doxorubicin was almost identical to that of free
doxorubicin.
3.3.2.2 pH-Responsive Release ofDoxorubicin
Fig. 3.6 shows the release of doxorubicin from DHD conjugates at pH's of 5.0 and 7.4 at
370 C. At a pH of 5.0, the rate of release was significantly greater than that at the extracellular
pH of 7.4 for all MW's, indicating that these conjugates would release the active drug inside an
endosome or lysosome. There was some release from the conjugate at pH 7.4 as well, though the
percentage released was significantly less than that at pH 5.0. The doxorubicin that was not
released from the conjugate might have reacted by a different mechanism to form a stable amide
bond with the dextran [29].
The release rate of doxorubicin from the conjugates of different MW's at a pH of 5.0 is
shown in Fig. 3.7. The initial release rate at a pH of 5.0 from the 10 kDa polymer conjugate was
up to 5-fold higher than the other conjugates. For both the 10 kDa and 40 kDa DHD conjugates,
there was an initial increase in the rate for the first 6 h, followed by a decline. The 70 kDa and
170 kDa DHD conjugates showed a lower and highly variable release rate. The release rate in a
pH 7.4 buffer remained relatively constant or declined over the 24 h period (data not shown).
The initial release of doxorubicin from the 10 kDa DHD conjugate at a pH of 5.0 was about 5-10
times faster than that at a pH of 7.4. This was comparable to the release profiles for hydrazone-
linked drugs reported in the literature [30].
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Fig. 3.6. Release of doxorubicin from DHD conjugates of MW's of (.) 10 kDa, (e) 40 kDa, (m)
70 kDa and (A) 170 kDa at a pH of (a) 5.0 and (b) 7.4. Values are mean ± standard deviation; n
= 3.
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Fig. 3.7. Rate of doxorubicin release from DHD conjugates of MW's of (.) 10 kDa, (*) 40 kDa,
(m) 70 kDa and (A) 170 kDa at a pH of 5.0.
3.3.3 In Vitro Studies
3.3.3.1 Doxorubicin Uptake
Flow cytometry was used to determine the excess fluorescence of cells incubated with
either doxorubicin or polymer-bound doxorubicin conjugates. The relative fluorescence of cells
incubated with the conjugates is illustrated in Fig. 3.8. The uptake of free doxorubicin was
significantly greater than the uptake of the conjugates. The MW of the carrier polymer did not
seem to have a significant effect on the uptake of the conjugates. The uptake of the acid-labile
DHD conjugates was greater than the non-targeted DD conjugates at equivalent MW's (Fig. 2.7)
[2]. A possible explanation for this was that doxorubicin was released from the DHD conjugate
in acidic intracellular vesicles, which allowed it to enter the nucleus easily. In contrast,
doxorubicin bound stably to dextran could be exocytosed before it had a chance to enter the
nucleus.
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Fig. 3.8. Doxorubicin-associated fluorescence of cells incubated for 24 h with (A) doxorubicin,
DHD conjugates of MW's of (*) 10 kDa, (e) 40 kDa, (n) 70 kDa and (A) 170 kDa. Values are
mean ± standard deviation; n = 3.
3.3.3.2 Cytotoxicity Studies
The cytotoxicity of the conjugates was determined using the MTT assay, which is a
simple and rapid colorimetric method for measuring cell viability. The concentration
corresponding to 50% cell death (LC 5o) was determined from the slope and intercept of the
straight line obtained by inverting the dose vs. cell death data from the dose response curves.
The LC 5o values obtained by this method were corroborated by determination with a logistic
model.
Cytotoxicity profiles for the conjugates were shown in Fig. 3.9. The DHD conjugates
were significantly more toxic than the stable DD conjugates. For example, the LC50 of DHD 10
kDa was 7.4 ýpM (Table 3.2), whereas LC50 of DD 10 kDa was 36.4 pM (Table 2.4) [2]. In our
previous work, we observed a significant increase in toxicity with increasing MW of DD
conjugates due to an increase in the chain loading (Table 2.4) [2]. However, we did not observe
the same effect with the DHD conjugates. The higher MW conjugates had a greater doxorubicin
loading, and would be able to carry more of the drug into the cell. However, as shown in Fig.
3.7, release from the DHD 10 kDa conjugate was much more rapid, and therefore, could lead to
greater accumulation of doxorubicin inside the cells. This may be corroborated by the slightly
greater uptake of DHD 10 kDa as observed in Fig. 3.8. Since these two effects opposed each
other, the MW did not have a strong overall effect on cytotoxicity.
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Fig. 3.9. Dose response curves of BNL CL.2 cells incubated for 24 h with (A) doxorubicin, and
DHD conjugates with MW's of (.) 10 kDa, (e) 40 kDa, (,) 70 kDa and (A) 170 kDa. Values are
mean + standard deviation; n = 3.
Table 3.2. LC50 of DHD conjugates in BNL CL.2 cells.
Conjugate MW (kDa) LC50 (pM)
10 7.4
40 8.5
70 8.8
170 9.2
Ulbrich et al. have reported a comparison of cytotoxicity of free doxorubicin and pH-
sensitive HPMA-doxorubicin conjugates in EL4 T cells [7]. They found that the doxorubicin
attached through a hydrazone bond had a LC50 value of 7-34 times that of free doxorubicin.
When they attached anti-Thyl.2 antibody to target the cells, the LC 0o was the same as free
doxorubicin. The DHD conjugates had LC 0o values that were 4-5 times higher than that of free
doxorubicin (1.8 pM). Attempts on galactose conjugation with the pH-sensitive synthesis were
unsuccessful because the polymer became insoluble.
3.3.3.3 Cell Cycle Analysis
The DNA content of cells treated with free doxorubicin, DHD and DD conjugates were
analyzed to investigate if treatment by free or conjugated doxorubicin yielded a difference in the
cell cycle response. As shown in Table 3.3, free doxorubicin caused cell cycle arrest in the
G2/M phase, with a significant increase in the number of cells in the S phase as well. Cells
treated with the acid-labile DHD 10 kDa conjugate showed a response very similar to free
doxorubicin. Cells treated with stably bound DD 10 kDa conjugate also exhibited G2/M phase
arrest. However, the percentage of cells in the S phase did not increase, indicating that the
mechanism of action of the DD conjugate differed from that of free doxorubicin and doxorubicin
delivered by the DHD conjugate. We previously showed that the ability of the DD 10 kDa
conjugates to intercalate with DNA was lower than that of free doxorubicin (Fig. 2.5) [2]. It is
possible that due to the weaker DNA binding, cells treated with DD 10 kDa were able to undergo
DNA replication in the S phase and enter mitosis, resulting in accumulation only in the G2/M
phase of the cell cycle.
Table 3.3. Percentage of BNL CL.2 cells in different phases of the cell cycle before and after
treatment with doxorubicin or conjugates.
Phase Untreated Doxorubicin DHD 10 kDa DD 10 kDa
GO/G1 84.5 14.1 12.0 28.2
S 4.6 16.0 14.9 2.1
G2/M 10.4 70.3 73.6 69.4
3.3.3.4 Internalization of Doxorubicin and Polymer Conjugates
Cancerous cells expel vast quantities of lactic acid, which results in the acidic
environment in a tumor [31]. Therefore, a pH-sensitive delivery vehicle may release the drug
before it is internalized by the cells. Live cell imaging was used in an attempt to examine the
mechanism of action of the DHD conjugates.
LysoTracker is a fluorophore conjugated to a weak base that freely passes through the
cell membrane and selectively localizes in low-pH intracellular vesicles. This green dye was
used to stain endosomes and lysosomes. The uptake of doxorubicin and DHD 10 kDa was
followed by confocal microscopy for I h (Fig. 3.10). For both the free drug and the polymer
conjugate, cellular uptake occurred within minutes. Free doxorubicin (red) was visible inside the
nucleus within 30 min of incubation. However, cells incubated with DHD 10 kDa did not show
nuclear uptake until at least 60 min after incubation. Also, for cells incubated with DHD 10 kDa,
there was significant colocalization (yellow) of fluorescence from doxorubicin and LysoTracker,
indicating that the polymer-conjugated doxorubicin was taken up by endocytic pathways. Free
doxorubicin did not show much colocalization since the doxorubicin was able to diffuse freely
through the cell.
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Fig. 3.10. BNL CL.2 cells incubated with (a-d) doxorubicin and (e-h) DHD 10 kDa at a
nominal doxorubicin concentration of 9 [M at the stated times. Acidic intracellular vesicles
were counterstained with LysoTracker Green. Scale bar = 20 Pm.
From release studies at pH 5.0 (Fig. 3.5), it can be seen that a very small percentage of
doxorubicin was released from the DHD conjugates within 1 h. Since the conjugates were taken
into the cells within a few minutes, it is unlikely that they released doxorubicin outside the cell
membrane. The DHD conjugates were possibly taken into the cells intact, and released
doxorubicin in the intracellular vesicles. Since cellular trafficking occurs very rapidly, it was
possible that the conjugates underwent multiple endocytosis and exocytosis cycles before the
doxorubicin was released.
Fig. 3.11 shows the confocal laser scanning microscopy images of BNL CL.2 cells
incubated with doxorubicin, DHD 10 kDa and DD 10 kDa for 4 h, with the nuclei counterstained
with SYBR Green. Free doxorubicin was localized exclusively in the nucleus, as observed from
the co-localization of doxorubicin and SYBR Green fluorescence. The fluorescence micrographs
of cells incubated with DHD conjugates also exhibited significant co-localization. In
comparison, the DD conjugate showed much less co-localization. These micrographs confirmed
that the doxorubicin on the DHD conjugates entered the nuclei efficiently, indicating that
doxorubicin was released from the polymer in an intracellular vesicle.
Fig. 3.11. BNL CL.2 cells incubated with (a) doxorubicin, (b) DHD 10 kDa and (c) DD 10 kDa
for 4 h at a doxorubicin concentration of 3.6 pM. The nuclei were counterstained with SYBR
Green. Scale bar = 10 ptm.
3.4 Summary
In our previous work, we had synthesized galactose-expressing doxorubicin delivery
vehicles, which were effective at targeting hepatocytes; however, the cytotoxicity was limited
since the doxorubicin remained attached to the polymer. In this work, we prepared pH-sensitive
dextran-doxorubicin conjugates of different MW's. Doxorubicin was attached through a
hydrazone bond to the dextran backbone. These polymer conjugates were stable at a
physiological pH of 7.4, but released over 70% of the attached doxorubicin within 24 h at a pH
of 5.0. The rate of release was found to be much faster for the lower MW polymers. In cell
culture studies, the conjugates showed significant cytotoxicity. The effect of lower chain loading
of doxorubicin in the lower MW polymers was offset by the rapid initial release rate of
doxorubicin. Consequently, the lower MW polymers showed slightly greater toxicity.
Confocal microscopy images showed that the polymer conjugates were taken into the
cells within minutes after incubation. Since release of doxorubicin from the conjugates occurred
over hours, it was likely that intact conjugates were taken up by cells and the drug was released
in intracellular vesicles. The conjugates might have gone through multiple endocytosis and
exocytosis cycles before the doxorubicin was released.
Doxorubicin from the DHD conjugates was found to localize almost exclusively in the
nuclei of cells. Since doxorubicin attached to dextran with a stable bond showed limited
localization in the nuclei, this confirmed that doxorubicin from the acid-labile conjugates was
released after internalization by cells. The cytotoxicity of the DHD conjugates was significantly
greater than the stable conjugates due to the effective release of doxorubicin inside cells.
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Chapter 4 - Synthesis, Characterization and In Vitro Studies of a Temperature- and pH-
Sensitive Polymer and its Use in Targeted Delivery of Paclitaxel to Hepatocytes
4.1 Introduction
Site-specific transport of drugs ensures that narrow therapeutic window drugs such as
chemotherapeutic agents are localized at the target site. Site-specific release or activation of
drugs after reaching the target site helps to ensure high therapeutic efficacy, and to maintain the
mechanism of action of the free drug. The combination of site-specific delivery and release
yields a drug delivery vehicle more effective than either one could be individually. Rihova et al.
have conducted a significant amount of research on poly((N-2-hydroxypropyl)methacrylamide)
(HPMA) conjugates for the delivery of chemotherapeutic agents. They have attached the pH-
sensitive conjugate HPMA-hydrazone-doxorubicin to anti-thymocyte globulin to target T cell
lymphoma EL4 cells. The in vitro toxicity of the targeted, pH-sensitive conjugate was
comparable to that of free doxorubicin [1].
Drugs encapsulated in micelles, liposomes or particles are protected from degradation or
prematured metabolism, and have longer plasma circulation times. If the release mechanism is
stimuli-responsive, a therapeutic level of the drug can be sustained over days or even months [2].
There has been much research on folate targeted delivery since folate receptors are over-
expressed on various forms of cancers [3]. Yoo et al. have formed biodegradable micelles from
block copolymers of poly(D,L-lactic-co-glycolic acid) (PLGA) and poly(ethylene glycol) (PEG)
[4]. Doxorubicin was attached to the PLGA end, and folate was attached to the PEG end of the
block copolymers. Micelles were formed by utilizing the hydrophobic PLGA segment and free
doxorubicin was encapsulated. The folate targeted micelles reduced the lethal median
concentration in cell culture studies by 33%. In vivo studies have shown increased accumulation
of doxorubicin in tumors due to folate receptor targeting, and significant regression of tumor size
[4]. Lee et al. have synthesized folate targeted micelles that are fine-tuned to release at a pH
between 6.6 and 7.2. They used poly(L-histidine) and poly(lactic acid)-PEG block copolymers
to encapsulate doxorubicin. The L-histidine component was thought to aid in endosomal escape
by fusing with the intracellular membranes [5]. Release studies and in vitro experiments in a
controlled pH environment showed rapid release in a narrow pH range and a corresponding
increase in cytotoxicity that was comparable to free doxorubicin [5].
Poly(N-isopropylacrylamide) (NIPAAm) is a well-known temperature-sensitive polymer
that is soluble in water below its lower critical solution temperature (LCST) of 320C, but
becomes hydrophobic and aggregates above that temperature. Though there is concern about the
carcinogenic effects of acrylamides in food, research on polyacrylamides has shown them to be
biocompatible [6, 7]. Much research has been conducted on the use of thermosensitive NIPAAm
polymers and copolymers for drug delivery. Prednisone acetate, an anti-inflammatory drug, has
been encapsulated in micelles formed from copolymers of NIPAAm and 10-undecenoic acid
(UA). The micelles were found to be pH-responsive only at temperatures above 31 C, which
was the LCST of the block copolymer [8]. Yang and co-workers have used poly(NIPAAm-co-
dimethyl acrylamide) and PLGA block copolymers to encapsulate paclitaxel in micelles. The
drug was released above the copolymer's LCST of 39.5°C, and the micelles had an LC50 value
that was an order of magnitude lower than that of free paclitaxel [9]. Such a system could be
utilized in drug delivery by local heating at the target site. They have also synthesized a
copolymer of NIPAAm, N,N-dimethyl acrylamide (DMAAm) and UA with an LCST of - 37oC,
and encapsulates doxorubicin in micelles [10].
We have adapted the last mentioned system, which was originally developed by
Soppimath et al. [11]. An ideal drug delivery system would be thermo-responsive at low pH
only. At physiological temperature and pH, the LCST would be greater than 370C, but at a
lower pH it would be lower than 370 C. It is well established in the literature that conjugating a
polymer of NIPAAm to another hydrophilic polymer or moiety increases the phase transition
temperature by increasing the hydrophilicity. On the other hand, attaching a hydrophobic moiety
would have the opposite effect and decrease the LCST [12]. DMAAm was included in the
polymer to increase the LCST of NIPAAm above 320C. The UA served two functions. It
contained a long hydrocarbon chain that allowed the polymer to form vesicles in the aqueous
medium. In addition, the carboxylic acid group would trigger the temperature sensitivity of the
NIPAAm. It would be protonated at a low pH, and the neutral charge would make it more
hydrophobic. This would lower the LCST of NIPAAm, and the polymer would become
hydrophobic. We targeted these copolymers to hepatocytes by expressing galactose on the
polymer.
The hydrophobic core of our particles was used to encapsulate paclitaxel - a hydrophobic
chemotherapeutic agent of the taxane family that is often used for cancers that do not respond
well to other conventional drugs. Paclitaxel is administered intravenously in Cremophor EL (a
mixture of polyoxyethylated castor oil and dehydrated ethanol) to treat lung, ovarian, breast,
head and neck cancers, and advanced forms of Kaposi's sarcoma [13, 14]. It has a plasma half-
life as low as 6 min, and is cleared through hepatic metabolism, biliary excretion, fecal
elimination and tissue binding. Its terminal half-life from organs and tissues varies from 14 to 50
h [14]. Paclitaxel acts by interfering with the assembly of the mitotic spindle, and preventing the
chromosomes from segregating during cell division. This inhibits cell proliferation and leads to
cell death. In cell culture studies, cell death has been found to occur via both apoptotic and non-
apoptotic mechanisms [13, 15]. The side-effects for this drug include hypersensitivity,
neutropenia, neurotoxicity, disturbance of cardiac rhythm and mucositis [14]. Delivery of
paclitaxel is a challenge due to its extremely low solubility in aqueous medium. Encapsulating
the drug in targeted micelles or particles with a hydrophilic shell would effectively increase its
solubility and delivery to the target sites.
The goal for this study was to synthesize galactose-targeted copolymers of NIPAAm,
DMAAm and UA with physical properties and thermo-responsiveness that would be appropriate
for drug delivery. Paclitaxel would be encapsulated in polymeric particles, which would be
examined for targeting and stimuli-responsive release in cell culture studies.
4.2 Experimental Methods
4.2.1 Materials
NIPAAm, DMAAm, UA, n-hexane, ammonium persulfate (APS), 2-aminoethanethiol
hydrochloride (AET-HC1), sodium hydroxide (NaOH), sodium chloride (NaC1), dimethyl
formamide (DMF), pyrene, D-lactose, sodium cyanoborohydride (NaBH3CN), boric acid,
Ricinus communis Agglutinin (RCA 120), HPLC grade tetrahydrofuran (THF), phenol, sulfuric
acid, bovine serum albumin (BSA) and FITC-conjugated monoclonal anti-13-tubulin antibody
were obtained from Sigma-Aldrich. NIPAAm was further purified by crystallization in n-
hexane. DMAAm and UA were also further purified by reduced pressure distillation. All other
chemicals were used as received from Sigma-Aldrich. Acetone, methanol, chloroform, 10x
phosphate buffered saline (PBS), and Dulbecco's l x sterile PBS containing calcium and
magnesium for cell culture studies were obtained from VWR. The cell lines BNL CL.2 and
NIH/3T3, Dulbecco's Minimum Essential Medium (DMEM), fetal bovine serum (FBS), 10,000
I.U./mL of Penicillin-10,000 gg/mL of Streptomycin, 0.25% of Trypsin/0.53 mM of
ethylenediaminetetraacetic acid (EDTA), and the MTT Cell Proliferation Assay kit were
obtained from American Type Culture Collection (ATCC). Propidium iodide (PI) and RNase A
were obtained from Invitrogen. Paclitaxel was purchased from LC Laboratories.
4.2.2 Polymerization of N-Isopropylacrylamide, N,N-Dimethylacrylamide and 10-
Undecenoic Acid
Fig. 4.1 shows a schematic of the polymerization of NIPAAm, DMAAm and UA.
NIPAAm and DMAAm (0.2 g) were dissolved in deionized (DI) water with the
NIPAAm:DMAAm molar ratio varied from 1 to 5. UA (0.1 to 0.5x molar ratio to DMAAm)
was dissolved in 1 M of NaOH solution and added to the solution of NIPAAm and DMAAm
with total monomer concentrations ranging from 0.1 to 0.4 mg/mL. The pH was adjusted to
between 6.5 and 6.8 by addition of dilute HC1. The mixture was then purged with nitrogen for
30 min. Solutions of APS (0.00125 to 0.00625x molar ratio to monomers) and AET-HCl (2x
molar ratio to APS) were added dropwise sequentially, and the reaction proceeded under a
nitrogen seal for 12-96 h. The polymer was precipitated by adding NaCl solution (10 M),
subsequently dissolved in ethanol, and purified by dialysis in a membrane with a molecular
weight cut-off (MWCO) of 2000 against DI water. The water was changed twice a day over 5
days, and the polymers were recovered by lyophilization.
Combine monomers in aqueous
medium at pH 6.5-6.8.
Purge with N2
Add APS and
AET-HCl
Reaction proceeds under N2 seal for
up to 96 h
Precipitate polymer with excess NaCI
Purify by dialysis against water and
lyophilize
Fig. 4.1. Schematic of synthesis ofpoly(NIPAAm-co-DMAAm-co-UA) [ 11].
4.2.3 Characterization of Polymer
4.2.3.1 Composition and Physical Properties
Photoacoustic Fourier-transform infrared (PA-FTIR) spectroscopy (Bio-Rad FTS60A)
and 1H nuclear magnetic resonance (NMR) spectroscopy (Avance DMX 400 MHz, Bruker) were
used to confirm the presence of all three monomers in the polymer. NMR was also used to
determine the ratio of NIPAAm to DMAAm in the polymer. The content of UA was estimated
from the number of carboxylic acid groups determined by acid-base titration. The polymer was
dissolved in 0.01 M of NaOH at a concentration of 1 mg/mL. The solution was back-titrated
with 0.01 M of HC1, and the moles of carboxylic acid groups on the polymer were determined
from the volume of titration.
The molecular weights (MW's) and polydispersity indices (PI's) were determined by gel
permeation chromatography (GPC) (Waters 2695D Separations Module, mobile phase of THF at
1.0 mL/min, relative to polystyrene standards) [11]. Differential scanning calorimetry (DSC)
(TA Instruments DSC Q100) was used to determine the glass transition temperature (Tg) of the
polymers. A sample of 10-15 mg was loaded in a standard pan. The temperature was initially
decreased to 00 C, and then raised to 2000 C at a ramp of 20 0 C/min. The decomposition
temperature (Tdec) was determined using thermal gravimetric analysis (TGA) (PerkinElmer Pyris
1 TGA). A sample of 5-10 mg was taken to a temperature of 700'C at a ramp of 100 C/min.
4.2.3.2 Lower Critical Solution Temperature
The LCST was determined by measuring the optical transmittance of a solution of blank
particles as a function of temperature. A solvent extraction/evaporation method was used to
form the particles. 10 mg of the polymer was dissolved in 1 mL of acetone, added drop-wise to
5 mL of DI water, and sonicated for 15 min. The acetone was allowed to evaporate by stirring
for 6 h, and the particles were dialyzed in a 50,000 MWCO membrane against DI water. The
particles were recovered by lyophilization, and redispersed in 1 x PBS at a pH of 7.4 or 5.0 at a
concentration of 5 mg/mL. Transmittance measurements were obtained with an ultraviolet-
visible (UV-Vis) microplate reader (VersaMax, Molecular Devices) at 450 and 650 nm as a
function of temperature between 250 C and 450 C. The particle solutions were allowed to stabilize
at each temperature for 5 min before the measurement. The LCST was defined as the
temperature at the inflection point of the transmittance curve [16].
4.2.3.3 Critical Aggregation Concentration
A fluorescent probe method was used to determine the critical aggregation concentration
(CAC) of the polymers [17]. The probe, pyrene was dissolved in methanol at a concentration of
1 mM, and was subsequently diluted in water near its saturation of 6x 10-7 M. Polymer solutions
of concentrations ranging from 0.001 to 50 mg/mL were prepared in the pyrene/methanol/water
solution. The solutions containing polymer were allowed to stabilize overnight on an orbital
shaker at 100 rpm. Excitation spectra were measured on a Tecan Safire2 from 300 to 360 nm
with emission at 390 nm. The ratios of the emission at 344 nm to that at 335 nm were plotted
against the concentration of the polymer. The CAC was defined as the concentration at the
intersection between the two straight lines that defined the curve.
4.2.4 Incorporation of Galactose onto the Polymer Chain
The polymer (200 mg) was dissolved in a sodium borate buffer (200 mM, pH 9.0) at 1
mg/mL. D-lactose (up to 100x molar ratio to the amine groups on the polymer) and a 5-fold
excess of NaBH 3CN relative to lactose were added to the polymer; the reaction was allowed to
proceed for up to 48 h at 300C [18]. The amount of lactose conjugated was determined using the
phenol-sulfuric acid assay [19]. Lactose-conjugated polymer (2 mg/mL in DI water (1 mL)) was
added to 1 mL of 5% phenol in DI water, followed by 5 mL of sulfuric acid. The absorbance
was measured at 490 nm. The standard curve was determined using galactose.
4.2.5 Formation and Characterization ofPaclitaxel-Loaded Particles
4.2.5.1 Synthesis ofPaclitaxel-Loaded Particles
Paclitaxel-loaded particles were formed from a similar method as the synthesis of blank
particles. Paclitaxel was added to the polymer/acetone solution with an initial paclitaxel:polymer
weight ratio of 0.2 to 1.0. The excess paclitaxel that was not encapsulated by polymer was
removed after dialysis by centrifugation at 3000 rpm for 1 min. The particles were recovered by
decanting and lyophilizing the supernatant.
4.2.5.2 Characterization of Paclitaxel-Loaded Particles
The presence of paclitaxel in the particles was confirmed by 1H NMR spectroscopy in
D20 and CDC13. The amount of paclitaxel loaded was measured by dissolving the particles in a
1:1 volume mixture of methanol and DMF, and measuring the absorbance at 261 nm. Drug
loading was defined as the mass of paclitaxel loaded in the particles divided by the total mass of
particles. The loading efficiency was defined as the mass of paclitaxel loaded in the particles
divided by the mass of paclitaxel introduced during synthesis. Transmission electron microscopy
(TEM) was conducted on a FEI Tecnai G2 F20 electron microscope (200 kV) to examine the size
and shape of the particles. Particle size was determined by sizing - 100 particles from each
sample. The availability of galactose residues on the particle surface was investigated using a
multivalent galactose-binding lectin RCA 120. The turbidity of a solution of 100 PLg/mL of
RCA 12o and 100 pg/mL of particles was measured at 450 and 650 nm before and after the
addition of 50 pL of 20 mg/mL of galactose [18]. The crystallinity of the particles was
investigated using X-ray diffraction (XRD) (PANalytical X'Pert PRO).
4.2.5.3 Release ofPaclitaxel
Paclitaxel-loaded particles were suspended in pH 5.0 or 7.4 buffer with an initial
paclitaxel loading of 40 jtg/mL. The particles were incubated at 370 C on an orbital shaker at 150
rpm. At each time point, the released paclitaxel was isolated by centrifuging the mixture at 3000
rpm for 1 min, and decanting the release buffer containing the particles. The paclitaxel was
subsequently extracted with chloroform, which was evaporated, redissolved in a 1:1 volume
mixture of methanol and DMF, and quantified by measuring the absorbance at 261 nm.
4.2.6 In Vitro Efficacy of Paclitaxel-Loaded Particles
The BNL CL.2 (mouse hepatocyte) and NIH/3T3 (mouse fibroblast) cell lines were
cultured in DMEM supplemented with 10% FBS and 1% Penicillin-Streptomycin at 370 C in 5%
of CO2.
For cytotoxicity studies, cells were plated (n = 6) at 100/mm 2 in 96-well plates, and
allowed to adhere for 10-14 h. The medium was then replaced with complete medium
containing paclitaxel or paclitaxel-loaded particles at various concentrations, and incubated for
24 h. At the end of the experiment, the cell layer was gently washed three times with cold PBS
and 100 ýtL of fresh medium. 10 pL of the MTT reagent (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) were then added, and the plate was incubated for 1 or 2 h. 100 pL
of sodium dodecyl sulfate were then added, and the cells were incubated for another 10 or 12 h.
The absorbance was measured at 570 nm. The standard curves for viable cell numbers were
obtained by performing the MTT assay on a known cell concentration curve, measured by
hemacytometer.
The time required for uptake of particles was determined by a timed cytotoxicity study.
Cells were prepared as above, and incubated with paclitaxel or paclitaxel-loaded particles at a
nominal paclitaxel concentration of 0.1 ýtM up to specific time-points. The medium was then
replaced with drug-free complete medium, and the cell viability was determined using the MTT
assay after a total incubation period of 24 h.
For microscopy studies, cells were plated at 100/mm 2 in chambered slides (Lab-Tek
Chambered Coverglasses, NUNC) and allowed to adhere for 10-14 h. The medium was then
replaced with complete medium containing paclitaxel or paclitaxel-loaded particles at a
normalized concentration of 0.1 [tM, and incubated for 24 h. The cell layer was gently washed
three times with cold PBS, and fixed in cold methanol for 20 min at -200 C. The cells were
subsequently washed three times with cold acetone and rehydrated in PBS for 30 min. They
were incubated at room temperature for 1 h in 38 jtg/mL of FITC-conjugated anti-p3-tubulin
antibody. The nuclei were counterstained with 1 gg/mL of PI for 30 min at room temperature.
The cell layer was washed with PBS to remove excess markers. Confocal images were obtained
on an Olympus IX71.
The DNA content of treated cells was analyzed by flow cytometry. Cells were treated
with paclitaxel or paclitaxel-loaded particles for 24 h at a nominal paclitaxel concentration of 0.1
[iM. The cells were then harvested, washed twice with calcium- and magnesium-free PBS,
redispersed in PBS, and fixed in cold ethanol overnight at 40 C. After fixation, the cells were
washed twice with PBS containing 1% of BSA, and redispersed in the PBS solution. PI and
RNase were then added at final concentrations of 50 jtg/mL and 1 mg/mL, respectively. The
cells were incubated at 370 C for 30 min, and analyzed by flow cytometry (BD FACSCalibur).
4.3 Results and Discussions
4.3.1 Characterization ofPoly(NIPAAm-co-DMAAm-co-UA)
4.3.1.1 Composition and Physical Properties
A schematic of the polymerization of NIPAAm, DMAAm and UA is illustrated in Fig.
4.2. The polymerization was confirmed by the absence of the monomer vinylic protons between
5.4 to 6.6 ppm in the 'H NMR spectrum of poly(NIPAAm-co-DMAAm-co-UA) (Fig. 4.3(a)).
The signals at 1.2 and 2.9 were attributed to the methyl protons of NIPAAm and DMAAm,
respectively, and the integrated areas of these peaks were used to determine the molar ratio of the
two monomers on the polymer. The peak at 4.0 ppm was due to the iso-propyl proton on
NIPAAm, and the broad peaks between 1.5 to 2.6 ppm were from the methylene groups on
NIPAAm and DMAAm. The PA-FTIR spectrum (Fig. 4.3(b)) exhibited peaks at - 1540, 1645
and 1711 cm 1- , which corresponded to the DMAAm amine (C-N), NIPAAm carbonyl (C=O)
and UA carbonyl groups, respectively [10]. The peaks above 3000 cm -1 were due to the amine
groups (N-H).
The compositions of the polymers used in in vitro studies are given in Table 4.1. The
relative content of NIPAAm to DMAAm was easily controlled by the precursor ratio of the two
monomers. The UA content in the final polymer could be adjusted by changing the molar ratios
of APS:monomers and NIPAAm:DMAAm, and the total monomers concentration. The Tg of the
polymers ranged from - l10 0 C to 140 0 C, and the decomposition temperatures were - 285-
306'C (Table 4.1).
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Fig. 4.2. Synthesis scheme of poly(NIPAAm-co-DMAAm-co-UA).
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Table 4.1.
1H NMR and (b) PA-FTIR spectra of poly(NIPAAm-co-DMAAm-co-UA).
Composition and physical properties of polymers used in in vitro studies.
NIPAAm DMAAm UA MW (kDa)
Tg (oC) Tdec (oC)(mol/mol) (mol/mol) (mol/mol) Mw PI
30 10 2 4.8 1.7 135 285
41 14 2 6.5 1.7 127 291
53 17 6 8.8 1.7 113 298
58 20 5 9.6 1.8 123 306
77 26 3 11.9 1.3 130 296
A xi /
1000 500
i I\ 1 ~ru ~
The MW's of the polymers ranged from 3 to 13 kDa. There was a large increase in MW
when the reaction time was increased from 12 to 24 h, followed bya plateau. A period of at least
24 h was used to ensure the completion of polymerization. The MW could be increased by
increasing the monomer concentration or decreasing the APS:monomer molar ratio (Fig. 4.4).
Bokias et al. have also found that the MW's of poly(NIPAAm) and poly(acrylic acid) were
proportional to the concentration of the monomer solution, and inversely proportional to the
concentration of AET-HCI [20].
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Fig. 4.4. MW's of polymers synthesized with varying (a) monomer concentrations and (b)
APS:monomer molar ratios.
4.3.1.2 Effect of Polymer Composition on LCST
As the content of DMAAm in the copolymer was increased, the LCST also increased due
to the increasing hydrophilicity of the polymer (Fig. 4.5(a)). At a pH of 7.4, the UA on the
polymer was deprotonated, and had little effect on the LCST (Fig. 4.5(b)). However, at pH 5.0,
the carboxyl groups were protonated, making the UA hydrocarbon chain more hydrophobic.
This imparted sufficient hydrophobicity to the polymer, so that the LCST was lowered and the
polymer was precipitated. As the content of UA was increased from 20 to 50 mg/g polymer, the
difference in LCST at the two pH's also increased. Polymers with a NIPAAm:DMAAm ratio of
> 3 and a UA content of 50 mg/g met the LCST criteria for a drug delivery vehicle.
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Fig. 4.5. LCST values of poly(NIPAAm-co-DMAAm-co-UA) with varying (a)
NIPAAm:DMAAm molar ratios (UA content > 50 mg/g polymer) and (b) UA contents
(NIPAAm:DMAAm = 3) at a pH of (m) 5.0 and (.) 7.4.
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4.3.1.3 Effect of Polymer Composition on Critical Aggregation Concentration
The fluorescence of pyrene was quenched as it partitioned from an organic to an aqueous
phase. This was quantified from the excitation spectrum by measuring the ratio of the emission
(Ix) at 344 nm to that at 335 nm. As the polymer concentration increased, pyrene was partitioned
into the organic cores formed by aggregation of the hydrophobic UA groups, and the 1344/1335
ratio increased exponentially. The polymer concentration at the intersection of the two lines that
defined the curve was taken as the CAC.
It was shown previously that for the range of LCST required for drug delivery, the
polymers of interest must have a NIPAAm:DMAAm ratio of > 3. The CAC of the polymers
fitting that criteria were found to be independent of the NIPAAm:DMAAm ratio. As expected,
the CAC decreased with increasing UA content (Fig. 4.6). The CAC values for the polymer
were found to be significantly larger than other polymers used in drug delivery, implying that a
higher loading of polymer would be necessary to form micelles or particles. However, a higher
CAC value would improve particle stability and increase the maximum drug loading that could
be achieved for a particular system [21]. The LCST and CAC values of the polymers chosen for
in vitro studies are given in Table 4.2.
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Fig. 4.6. CAC values of poly(NIPAAm-co-DMAAm-co-UA) with varying UA contents.
Table 4.2. LCST, CAC and galactose substitution of polymers
Polymer MW LCST (oC) CAC GalactoseSubstitution(kDa) pH 7.4 pH 5 (mg/mL) (mol/mol)
4.8 41 35 2.6 0.69
6.5 42 36 2.9 0.73
8.8 41 37 1.7 0.66
9.6 41 36 2.5 0.70
11.9 42 33 3.2 0.74
4.3.1.4 Characterization of Galactose-Conjugated Polymer
The polymers synthesized have an amine end-group due to the chain transfer agent,
AET-HC1. This amine group was employed in a reaction with lactose to express galactose on
each polymer chain. Lactose is a disaccharide of D-glucose and P-D-galactose with a 31-4
glycosidic link. Galactose is a non-reducing locked ring, whereas glucose is a hemiacetal, which
can react with the amine groups on the polymer. The degree of galactose substitution was
optimized with a lactose:polymer molar ratio of 10 and a reaction time of 48 h (Fig. 4.7). The
galactose substitutions on the polymers used in this study are given in Table 4.2. The degree of
expression of galactose on the particles was controlled by adjusting the ratio of galactose-
substituted polymer used during particle synthesis. The particles were identified according to the
percentage of galactose-substituted polymer used during synthesis (i.e. 0, 50, 75 or 100%).
used in in vitro studies.
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Fig. 4.7. Degrees of galactose substitution with varying (a) lactose:polymer molar ratios
(reaction time = 48 h), and (b) reaction times (lactose:polymer molar ratio = 10).
4.3.2 Characterization of Paclitaxel-Loaded Particles
4.3.2.1 Encapsulation ofPaclitaxel
NMR spectroscopy was used to investigate the structure of the paclitaxel-loaded particles
(Fig. 4.8). In D20, the particles remained intact, and only the peaks due to the hydrophilic
segments of the polymer were visible. CDCl 3 dissolved the particles and paclitaxel, and the
peaks due to both the polymer and the hydrophobic paclitaxel were visible. This confirmed that
paclitaxel had been encapsulated in the polymer particles.
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Fig. 4.8. 1H NMR spectra of (a) paclitaxel in CDC13, (b) paclitaxel-loaded particles in CDC13,
and (c) paclitaxel-loaded particles in D20.
Sonication, paclitaxel:polymer mass ratio, and acetone:water volume ratio were found to
be important in determining the final paclitaxel loading in the particles. Particles that were not
sonicated had a loading that was over 50% lower than those that were sonicated during synthesis.
At a MW of 11.9 kDa, the loading increased from 10% to 25% with sonication. There was a
slight increase in loading with the polymer MW.
Fig. 4.9(a) illustrates that the paclitaxel loading approached a plateau at a
paclitaxel:polymer mass ratio of - 0.8. The efficiency of paclitaxel loading also increased and
reached a maximum of 49% at a paclitaxel:polymer mass ratio of 0.8. The acetone:water volume
ratio represented the speed of organic phase removal, and was a measure of the time for
interaction between the drug and the hydrophobic elements of the polymer while in the organic
phase. At low ratios, there was fast acetone removal, and less time to interact and structure the
particles. The loading initially increased as the acetone:water volume ratio was increased.
However, as the time of interaction was increased further, paclitaxel might partition with the
acetone during the dialysis step, and precipitate out of solution leading to decreased loading.
The paclitaxel loading efficiency reached a maximum of 83% at an acetone:water volume ratio
of 0.1. At an acetone:water volume ratio of 0.2, the efficiency was 53%. For particle synthesis,
a paclitaxel:polymer mass ratio of 0.8 and an acetone:water volume ratio of 0.2 were used to
maximize the paclitaxel loading.
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Fig. 4.9. Paclitaxel loadings
(acetone:water volume ratio =
mass ratio = 0.8). Polymer MW
of particles with varying (a) paclitaxel:polymer mass ratios
0.2), and (b) acetone:water volume ratios (paclitaxel:polymer
= 11.9 kDa. Values are mean ± standard deviation; n = 2.
4.3.2.2 Morphology ofPaclitaxel-Loaded Particles
Transmission electron microscopy showed that the paclitaxel-loaded particles were
cylindrical with high aspect ratios (Fig. 4.10). The diameters ranged from - 50 nm to 100 nm
and the lengths varied from 200 nm to 1000 nm. There was an increase in particle length with
increasing polymer MW (Table 4.3).
1.0 1.2
e
o.
E 0.2-
E
E
o, o.l-
00 0.1-CL I -cl
A
I- i i i r
Fig. 4.10. TEM images of paclitaxel-loaded particles with MW's of (a) 4.8, (b) 6.5 and (c) 11.9
kDa. Scale bar = 100 nm.
Table 4.3. Length of paclitaxel-loaded particles.
MW (kDa) Particle Length (nm)
4.8 363 ± 31
6.5 389 ± 90
8.8 528 ± 76
9.6 547 ± 84
11.9 556 ± 88
Most of the research on drug delivery vehicles has focused on the effects of particle size
and surface chemistry of spherical particles. Until recently, there have not been many simple,
reproducible methods to form non-spherical particles, and therefore, there has been little study
on the effect of particle shape [2, 22, 23]. Euliss et al. [23] and Champion et al. [24] have
recently developed methods that could be used to reproducibly synthesize large quantities of
particles with shapes as varied as rods, cones, disks, pellets, vases and donuts. Particle
morphology can affect the release and degradation properties, cellular interactions, flow
properties and diffusion rate. Zero-order release has been achieved from hemispheres with
release only from the flat face [25]. It has been shown recently that depending on the orientation
during cellular interaction, one length scale might be more important than others. Additionally,
the profile of the particle extending into flow conditions would determine the length of
attachment [2]. Due to adhesive properties, non-spherical particles might be able to carry more
drugs into the cells than spherical particles [26]. Geng et al. have synthesized flexible worm
micelles using PEG-poly(ethylethylene) or PEG-poly(caprolactone), and have shown that they
remain in circulation in rodents up to one week, which was ten times longer than the spheres.
The circulation time increased with the length of the micelles; under flow conditions, it was
easier for cells to internalize shorter or spherical micelles [27]. More thorough research is
required to investigate the advantages and disadvantages of using non-spherical particles in drug
delivery. Recent work on nanotubes has shown great potential with regard to drug loading and
release profiles from cylindrical particles [28].
The availability of galactose residues on the paclitaxel-loaded particles was investigated
using a turbidity assay. RCA 120 is a lectin from castor beans that has several galactose binding
sites on each unit [29, 30]. If the lectins have binded galactose from different particles, it would
cause particle aggregation, increasing the turbidity of the solution. Fig. 4.11 shows that the
turbidity of a solution containing galactose-expressing particles decreased when an excess of free
galactose was introduced into the mixture. This indicated that the galactose was available on the
surface of the particles.
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Fig. 4.11. Effect of galactose addition on the turbidity of paclitaxel-loaded particles with
galactose substitutions of (s) 0% and (.) 100%.
XRD was used to investigate the crystallinity of the encapsulated paclitaxel (Fig. 4.12).
The polymers were amorphous and free paclitaxel was crystalline. XRD of the particles
illustrated a lack of crystalline peaks, indicating that the paclitaxel solidified in an amorphous
U U U *' U U U
form. The amorphous form has been reported to be slightly more soluble in aqueous media than
the crystalline form [9]. It has been suggested that particles with higher drug loadings would be
crystalline and would release drugs more slowly [31-33]. However, our particles with paclitaxel
loadings as high as 39 wt% remained amorphous.
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Fig. 4.12. XRD patterns of (a) paclitaxel, and paclitaxel-loaded particles with galactose
substitutions of (b) 0% and (c) 100%.
4.3.2.3 pH-Sensitive Release ofPaclitaxel
Paclitaxel-loaded particles were found to be stable in aqueous medium, and were not
separated by centrifugation at the speeds and times used to isolate free paclitaxel. Release was
measured at pH's of 7.4 and 5.0 at 370 C. Paclitaxel release at tumor or endosmal conditions was
very rapid (Fig. 4.13), with at least 50% of the paclitaxel released within 1 h for all polymers
examined. This was comparable to the rate of release from Cremophor EL [34]. As designed,
our particles only released paclitaxel under the appropriate temperature and pH. After 24 h, the
release at a pH of 7.4 was only - 20%, whereas - 100% release was achieved at a pH of 5.0.
Since the particles did not aggregate and there was no burst release at a pH of 7.4, we could
presume that there was little or no paclitaxel on the surface of the particles. Fig. 4.14 shows the
release at a pH of 5.0 at 370 C for the different polymer MW's studied. Release from polymeric
particles of lower MW was slightly faster. Since all our particles were amorphous, the faster
release was attributed to the lower polymer MW and the smaller size of the resulting particles.
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Fig. 4.13. Paclitaxel release at 37oC and pH's of (.) 5.0 and (A) 7.4 from particles synthesized
from the 4.8 kDa polymer with 100% galactose substitution.
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Fig. 4.14. Paclitaxel release at 370 C and a pH of 5.0 from particles
with MW's of () 4.8, (e) 6.5, (A) 8.8, (x) 9.6, and (x) 11.9 kDa.
synthesized from polymers
4.3.3 In Vitro Studies
4.3.3.1 Cytotoxicity Studies on Target Cell Line
The MTT assay was used to measure the viability of cells treated with paclitaxel or
paclitaxel-loaded particles due to its high throughput nature and ease of use. Polymer and blank
particles had no effect on cell viability (data not shown). The dose response curves for cells
treated with the 4.8 and 6.5 kDa polymer particles with varying galactose substitutions are shown
in Fig. 4.15. The lethal median concentrations for particles of various MW's and galactose
substitutions for the BNL CL.2 cell line are shown in Table 4.4.
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Fig. 4.15. Viability of BNL CL.2 cells incubated for 24 h with (x) paclitaxel, and paclitaxel-
loaded of (a) 4.8 kDa and (b) 6.5 kDa with galactose substitutions of (*) 0%, (A) 50%, (-) 75%
and (*) 100%. Values are mean + standard deviation; n = 3.
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Table 4.4. LC 5so (M) of paclitaxel-loaded particles in BNL CL.2 cells.
% Galactose MW (kDa)
Substitution 4.8 6.5 8.8 9.6 11.9
0 4.7x10 -1  9.8x10' 1  9.0x101  1.1xl00 1.1xl00
50 5.7x10 -2  1.3x10' 4.2x10 -1  6.7x10 -1  7.7x10 -1
75 1.0x 10-2 1.0x10 -1  1.0x10 -1  1.9x101  2.7x10 -1
100 9.1x10 -4 7.0x10 -3 7.9x 10-3 7.5x 10-3 1.4x10 -2
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Fig. 4.16. Viability of BNL CL.2 cells incubated for 24 h with (x) paclitaxel, and paclitaxel-
loaded "control" or non-stimuli-responsive particles of 6.4 kDa with galactose substitutions of
(e) 0%, (A) 50%, (s) 75% and (*) 100%. Values are mean + standard deviation; n = 3.
The importance of stimuli-responsiveness was examined in cell culture experiments by
measuring the cytotoxicity of "control" or non-stimuli-responsive particles that have an LCST of
44'C at a pH of 7.4, and an LCST of 390 C at a pH of 5.0. Ideally, these non-stimuli-responsive
particles would not release in response to temperature and pH under cell culture conditions.
However, in in vitro studies, they exhibited some cytotoxicity (Fig. 4.16), indicating that there
was release of paclitaxel. There was some passive diffusion of paclitaxel out of the particles at
370 C at a pH of 7.4, as indicated in Fig. 4.13. The particles might also have been disrupted by
proteins or various intracellular membranes, leading to the release of paclitaxel. The lethal
median concentrations of these particles were 5.2, 3.1, 1.2 and 0.21 pM for 0, 50, 75 and 100%
100
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galactose-substituted polymer, respectively. These values were one to two orders of magnitude
higher than those for the stimuli-responsive particles at a similar molecular weight (6.5 kDa)
(Table 4.4).
The cytotoxicity of the stimuli-responsive, non-targeted particles was slightly higher than
that of free paclitaxel. The LCso values of paclitaxel and paclitaxel-loaded stimuli-responsive
particles (4.8 kDa, with 0% galactose substitution) for this cell line were 1.1 pM and 0.47 PM,
respectively (Table 4.4). In contrast, the non-stimuli-responsive particles with 0% galactose
substitution were less toxic than free paclitaxel. Since the polymer LCST was greater than 37°C,
even if the non-stimuli-responsive particles were internalized by cells, only the portion of the
drug that diffused out of the particles would become available to the cells.
As the galactose substitution was increased for the stimuli-responsive, targeted particles,
there was a significant reduction in the LC5o at all MW's (Table 4.4). The same trend was
observed for the non-stimuli-responsive particles, but to a lesser degree. At higher galactose
substitutions, there would be greater particle uptake by the target cell line. For the stimuli-
responsive particles, this led to a dramatic increase in toxicity since more particle uptake would
result in greater drug release under the pH- and temperature-sensitive conditions. For the non-
stimuli-responsive particles, this led to some increase in drug availability through diffusion from
a larger number of particles uptaken, and thus a moderate increase in toxicity.
There was a small decrease in toxicity with increasing polymer MW due to the slightly
slower release (Fig. 4.14). Since the effect of MW on the release was relatively minor,
especially at 24 h, the effect in in vitro studies was not pronounced.
In clinical studies, the peak plasma concentration of paclitaxel ranged from 0.2 to 3.5 iM
for a 24 h infusion [14, 35, 36]. Concentrations of 5x 103 to 0.2 iM were found to cause mitotic
arrest and cell death. In in vitro studies on the BNL CL.2 cell line, the lethal median
concentration of the particles were in this clinically relevant range for particles formed with
polymers that consisted of > 50% of galactose substitution (Table 4.4).
In a timed in vitro study, cytotoxicity was observed in cells incubated with paclitaxel-
loaded particles for as short a period as 1 h (Fig. 4.17). This indicated that in spite of the large
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size of the particles, uptake occurred very quickly. From the release studies (Fig. 4.13), we knew
that the stimuli-responsive release would occur very rapidly after uptake by cells.
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Fig. 4.17. Viability of BNL CL.2 cells incubated with (*) paclitaxel, paclitaxel-loaded particles
with 100% galactose substitutions and MW's of (n) 4.8 kDa and (A) 11.9 kDa. Values are mean
+ standard deviation.
BNL CL.2 cells treated with paclitaxel-loaded particles showed a rounded morphology in
light microscopy images, as consistent with those treated with free paclitaxel [13]. The effect of
paclitaxel or paclitaxel-loaded particles on the cytoskeleton was confirmed by staining
microtubules with a fluorescent antibody (Fig. 4.18). DNA fragmentation was also confirmed
with PI staining.
Paclitaxel is well-established as a mitotic inhibitor. The cell cycle analysis of cells
treated with paclitaxel or paclitaxel-loaded particles confirmed G2/M phase arrest (see Table
4.5). Lin et al. also showed that cell viability in paclitaxel-treated hepatocytes was mediated
through G2/M phase arrest and DNA fragmentation [13].
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Fig. 4.18. BNL CL.2 cells incubated with (a) no treatment, (b) paclitaxel, and paclitaxel-loaded
particles with galactose substitutions of (c) 0% and (d) 100% for 24 h. Nominal paclitaxel
concentration = 0.1 pig/mL. Polymer MW = 4.8 kDa. Scale bar = 20 ptm.
Table 4.5. Percentage of BNL CL.2 cell population in different phases of the cell cycle before or
after treatment with paclitaxel or paclitaxel-loaded particles. Nominal paclitaxel concentration =
0.1 tM. Polymer MW = 4.8 kDa, galactose substitution = 100%.
Treated with Treated with Paclitaxel-Phase Untreated Paclitaxel Loaded Particles
GO/G1 82 22 23
S 5 15 9
G2/M 13 62 65
4.3.3.2 Cytotoxicity Studies on Control Cell Line
Fig. 4.19 showed the cytotoxicity of paclitaxel and paclitaxel-loaded particles in the
control NIH/3T3 cell line. The LC 50 values of all the particles were comparable to that of free
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paclitaxel (1.2 jpM) (Table 4.6). There was no effect due to the galactose substitution in the
polymer, since NIH/3T3 cells do not over-express ASGP receptors.
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Fig. 4.19. Viability of NIH/3T3 cells incubated for 24 h with (x) paclitaxel, and paclitaxel-
loaded particles of 4.8 kDa with galactose substitutions of (o) 0%, (A) 50%, (m) 75% and (*)
100%. Values are mean + standard deviation; n = 3.
Table 4.6. LC50 (pM) of paclitaxel-loaded particles in NIH/3T3 cells.
% Galactose MW (kDa)
Substitution 4.8 6.5 8.8 9.6 11.9
0 1.5x10' 3.0x10 -1' 3.5x10 -1  8.3x10 -  1.0x100
50 2.0x10 -1  2.6x10 -1  3.9x10 -' 3.8x10 -1  7.0x10 -1
75 2.3x10 -' 3.7x10 -1' 5.2x10 -1  5.0x10 -1  7.9x10 -1
100 3.5x10 -' 4.5x10 -1' 3.5x10 -1  5.0x10 -1  5.6x10 -1
4.3.4 Effect of Galactose Substitution on LCso in Target and Control Cell Lines
The expression of galactose had a significant effect on the cytotoxicity of the paclitaxel-
loaded particles in the target BNL CL.2 cell line. Fig. 4.20 showed the ratio of the LC50 of
targeted particles to that for non-targeted particles synthesized from the same MW polymer as a
function of the percentage of galactose substituted polymer used to form the targeted particles.
The paclitaxel dosage needed to achieve the same cytotoxic effect was reduced by - 1-3 orders
of magnitude using the targeted particles with galactose substitution.
104
10-
· I · 1
-5
~
In contrast, the presence of galactose had no effect on the cytotoxicity towards the control
NIH/3T3 cell line. Fig. 4.21 shows the ratio of LC50 of targeted particles to that for non-targeted
particles synthesized from 4.8 kDa polymer as a function of the galactose substitution in the
targeted particles. Unlike for the BNL CL.2 cells, there was no appreciable change or trend in
toxicity due to galactose substitution on the polymer for the NIH/3T3 cells. This confirmed the
successful targeting of BNL CL.2 cells by the galactose-expressing particles.
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Fig. 4.20. Change in LC50 in BNL CL.2 cells incubated for 24 h with paclitaxel-loaded particles
with polymer MW's of (.) 4.8, (.) 6.5, (A) 8.8, (x) 9.6, and (x) 11.9 kDa, as a function of
galactose substitution in the targeted particles.
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Fig. 4.21. Change in LC5 0 in (*) BNL CL.2 and (n) NIH/3T3 cells incubated for 24 h with
paclitaxel-loaded particles with a polymer MW of 4.8 kDa, as a function of galactose substitution
in the targeted particles.
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4.4 Summary and Conclusions
Various synthesis parameters for a temperature- and pH-sensitive random copolymer of
NIPAAm, DMAAm and UA have been optimized to spontaneously form particles in an aqueous
medium. A range of compositions that yielded polymers with physical properties appropriate for
drug delivery has been identified. The desired LCST was obtained by adjusting the content of
DMAAm and UA to change the hydrophilicity of the polymer. The hydrophilicity of UA was
dependent on pH, and thus, made the polymer pH-sensitive. Galactose was attached to the end-
group of the polymer to target it to hepatocytes. MW was found to be an important property of
these polymers. The drug loading, particle size and release rate were affected by the polymer
MW.
Paclitaxel was encapsulated in stimuli-responsive particles that released nearly 100% of
the drug within 24 h at a pH of 5.0 at 370 C. The cytotoxicity of the stimuli-responsive, non-
targeted particles was slightly higher than that of free paclitaxel. In contrast, the non-stimuli-
responsive particles with no galactose substitution were less toxic than free paclitaxel. Since the
polymer LCST was greater than 370 C, even if the non-stimuli-responsive particles were
internalized by cells, only the portion of the drug that diffused out of the particles would become
available to the cells.
In the target hepatocyte cell line, the galactose-expressing particles had LC 50 values that
were 1-3 orders of magnitude lower than the non-targeted particles and free paclitaxel. At
higher galactose substitutions, there would be greater particle uptake by the target cell line. For
the stimuli-responsive particles, this led to a dramatic increase in toxicity since more particle
uptake would result in greater drug release under the pH- and temperature-sensitive conditions.
In the control cell line, as expected, the presence of galactose did not have any effect on
cytotoxicity.
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Chapter 5 - Recommendations for Future Work
5.1 Further Enhancement of Drug Delivery Systems
Several researchers have performed binding studies with various molecules that were
thought to mimic the binding site of the native asialoglycoprotein receptor ligand. These studies
have shown that the binding affinity increases significantly when the number of terminal
galactose residues was increased from one to three [1, 2]. The increase in affinity observed with
a tri-galactose substituted molecule is greater than what can be expected from a simple collision
theory effect. The multivalent structure is a general characteristic of carbohydrate ligands, and is
known as the "cluster effect" [3, 4]. Additionally, increasing the flexibility of the galactose
residues by putting a spacer molecule between the delivery vehicle and the targeting ligand also
improves the affinity by increasing the chances of binding in a specific orientation [5].
Attaching galactose or a tri-galactose molecule through a spacer, such as poly(ethylene glycol)
would improve the binding affinity of our drug delivery systems.
5.2 Mechanism of Action
It is important to identify the mechanism of action of a drug delivery vehicle. We
measured the cytotoxicity using the MTT assay and performed some preliminary mechanistic
studies with cell cycle analysis. However, assays that directly measure the effect of the drugs
being delivered would provide more detailed information about the influence of the delivery
vehicle. Doxorubicin leads to apoptosis by stabilizing an intermediate complex between DNA
and topoisomerase II [6]. Additionally, an increase in p53 expression is often associated with the
induction of apoptosis [7]. The levels of topoisomerase II and p53 can be measured to
investigate the direct effect of doxorubicin.
Paclitaxel acts by various mechanisms in different cell types at different concentration
ranges [8-10]. Since it stabilizes microtubules, the most direct measurement of the effect would
be to study the number of asters of mitotic spindles, which should increase after treatment.
Several proteins have also been associated with paclitaxel-mediated cell death, including Raf-1,
p53 and p21 [8]. The expression of these proteins could also be studied to investigate the
mechanism of action of the delivery vehicle.
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5.3 Applications to Other Drugs and Therapeutics
Several other anthracycline chemotherapeutic agents such as epirubicin, daunorubicin
and idarubicin can be conjugated to dextran through the same synthesis procedures given in
Chapters 2 and 3 [11, 12]. Docetaxel is a hydrophobic chemotherapeutic agent similar to
paclitaxel, which can be encapsulated in the polymer particles described in Chapter 4 [13].
Rifabutin (for advanced HIV treatment) and rifapentine (for pulmonary tuberculosis) are also
hydrophobic drugs that can be delivered using these particles.
Cancerous cells often are or can become resistant to a wide variety of exogenous toxins.
One mechanism is an over-expression of P-glycoprotein, which is a membrane transporter that
can bind many drugs and pump them out of the cell [14]. Attachment of a drug to polymers or
delivery through particles reduces the effect of multidrug resistance since the transporter cannot
expel anything larger than a small molecule drug. The drug delivery systems developed in this
work can be tested for effectiveness in in vitro studies using multidrug resistant cell lines.
Other than drug delivery, targeted delivery systems can also be utilized in gene delivery
and biomedical imaging. Fluorescent or radio-labeled markers can be encapsulated in the
polymer particles for imaging purposes [15].
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Chapter 6 - Conclusions
Cancer is a highly variable disease occurring in many organs. There is a need for
delivery systems that are easily adaptable for a number of targets in different forms of cancers,
and that can accommodate various cytotoxic drugs. The motivation of this project was to
develop flexible synthesis procedures for the targeted delivery of chemotherapeutic agents. In
this thesis, we have designed and tested three drug delivery systems.
A simple, efficient synthesis scheme was developed to conjugate doxorubicin to dextran
with varying degrees of galactose substitution to target hepatocytes. The synthesis scheme was
simple, efficient and easily adaptable to other therapeutic agents and targeting moieties with free
amine groups. In cell culture studies on the target cell line, the dextran-doxorubicin-galactose
(DDG) conjugates showed lower toxicity compared to doxorubicin, increased toxicity with
higher molecular weight (MW) polymers, and greater toxicity with higher degree of galactose
substitution. Experiments in the control cell lines showed increased toxicity for higher MW
polymers; however, there was no effect due to the presence of galactose. At diameters of 15-40
nm, the polymer conjugates were too large to enter the cell nuclei in large quantities, but
sufficient conjugates entered the nuclei to cause cell death. The higher MW polymers were more
effective since they had a higher chain loading of doxorubicin.
In spite of successful targeting, the cytotoxicity of the first system was limited since the
doxorubicin remained attached to the polymer. In the second system, we synthesized pH-
sensitive dextran-doxorubicin conjugates of different MW's. Doxorubicin was attached through
a hydrazone bond to the dextran backbone. These polymer conjugates were stable at a
physiological pH of 7.4, but released over 70% of the attached doxorubicin within 24 h at a pH
of 5.0. The rate of release was found to be faster for the lower MW polymers. In cell culture
studies, the conjugates showed significant cytotoxicity. The effect of lower chain loading of
doxorubicin for the lower MW polymers was offset by the rapid initial release, and they showed
slightly greater toxicity. Uptake of the conjugates occurred within minutes after incubation, and
since release occurred over hours, the conjugates might have gone through multiple endocytosis
and exocytosis cycles before the doxorubicin was released. Doxorubicin from the dextran-
hydrazone-doxorubicin (DHD) conjugates was found to localize almost exclusively in the nuclei
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of cells. Since doxorubicin attached to dextran with a stable bond showed limited localization in
the nuclei, this confirmed that doxorubicin from the acid-labile conjugates was released after
internalization by cells. The cytotoxicity of the DHD conjugates was significantly greater than
the stable DDG conjugates due to the release of doxorubicin inside cells.
In the third drug delivery system, the targeting and stimuli-responsive functionalities
were combined using an amphiphilic copolymer of N-isopropylacrylamide (NIPAAm), N,N-
dimethylacrylamide (DMAAm) and 10-undecenoic acid (UA). A range of compositions that
yielded polymers with physical properties appropriate for drug delivery has been identified. The
appropriate lower critical solution temperature (LCST) was obtained by adjusting the content of
DMAAm and UA to change the hydrophilicity of the polymer. The hydrophilicity of UA was
dependent on pH, and thus, rendered the polymer pH-sensitive. Galactose was attached to the
end-group of the copolymer to target it to hepatocytes. The drug loading, particle size and
release rate were affected by the polymer MW. Paclitaxel was encapsulated in particles that
released nearly 100% of the drug within 24 h at a pH of 5.0 at 370C. In the target hepatocyte cell
line, these stimuli-responsive, galactose-expressing particles had LC5 0 values that were 1 order of
magnitude lower than the non-stimuli-responsive particles, and 1 to 3 orders of magnitude lower
than the non-targeted particles. In the control cell line, as expected, the presence of galactose did
not have any effect on cytotoxicity.
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